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Abstract——Pre-, post-, and remote conditioning of
the myocardium are well described adaptive responses
that markedly enhance the ability of the heart to
withstand a prolonged ischemia/reperfusion insult
and provide therapeutic paradigms for cardioprotec-
tion. Nevertheless, more than 25 years after the discov-
ery of ischemic preconditioning, we still do not have
established cardioprotective drugs on the market. Most
experimental studies on cardioprotection are still under-
taken in animal models, in which ischemia/reperfusion is
imposed in the absence of cardiovascular risk factors.
However, ischemic heart disease in humans is a complex
disorder caused by, or associated with, cardiovascular
risk factors and comorbidities, including hypertension,
hyperlipidemia, diabetes, insulin resistance, heart fail-
ure, altered coronary circulation, and aging. These risk
factors induce fundamental alterations in cellular sig-
naling cascades that affect the development of ischemia/
reperfusion injury per se and responses to cardioprotective
interventions. Moreover, some of the medications used
to treat these risk factors, including statins, nitrates,
and antidiabetic drugs, may impact cardioprotection
by modifying cellular signaling. The aim of this article
is to review the recent evidence that cardiovascular
risk factors and theirmedicationmaymodify the response
to cardioprotective interventions. We emphasize the
ABBREVIATIONS: ACE, angiotensin-converting enzyme; AMPK, adenosine monophosphate–activated kinase; AT1, angiotensin II receptor
type 1; CCB, L-type calcium channel blocker; COX-2, cyclo-oxygenase-2; Cx43, connexin 43; Drp1, dynamin-related protein; eNOS, endothelial
NO synthase; ERK, extracellular signal-regulated kinase; GLP-1, glucagon-like peptide-1; GSK-3b, glycogen synthase-3b; KATP, ATP-sensitive
potassium channel; MI, myocardial infarction; MMP, matrix metalloproteinase; MPTP, mitochondrial permeability transition pore; PCI,
percutaneous coronary intervention; PI3K, phosphatidylinositol 3-kinase; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; PKG,
cGMP-dependent protein kinase; PTEN, phosphatase and tensin homologue; RISK, reperfusion injury salvage kinase; ROS, reactive oxygen
species; SAFE, survivor activating factor enhancement; Sirt1, sirtuin deacetylase 1; STEMI, ST-segment elevated MI; STAT3, signal transducer
and activator of transcription-3; TNFa, tumor necrosis factor a.
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critical need to take into account the presence of
cardiovascular risk factors and concomitant medications
when designing preclinical studies for the identification
and validation of cardioprotective drug targets and
clinical studies. This will hopefully maximize the success
rate of developing rational approaches to effective
cardioprotective therapies for the majority of patients
with multiple risk factors.
I. Introduction
Ischemic heart disease is one of the leading causes of
death and disability in the industrialized societies.
Effective treatment of acute myocardial infarction (MI)
is based on procedures that promote the return of
blood flow to the ischemic zone of the myocardium,
i.e., reperfusion therapy. Reperfusion, however, may
lead to further irreversible myocardial cell death,
termed lethal myocardial reperfusion injury. Currently,
there is no effective therapy for combined ischemia/
reperfusion injury on the market, and routine phar-
macologic agents do not salvage the ischemic/reperfused
myocardium. Therefore, the development of cardio-
protective agents to limit the extent of infarcted tissue
caused by ischemia/reperfusion injury is of great clinical
importance.
Earlier pharmacologic approaches to attenuate the
consequences of ischemia/reperfusion injury were of
limited experimental efficacy or failed to translate into
useful clinical treatments. However, in the last three
decades, the heart has been shown to possess a remark-
able ability to adapt to ischemia/reperfusion stress, and
this molecular plasticity of the heart in ischemia/
reperfusion has been the focus of intense research in
the hope that the underlying mechanisms may be
amenable to therapeutic exploitation. Ischemic precon-
ditioning, postconditioning, and remote conditioning of
myocardium are well described adaptive responses in
which there is brief exposure to ischemia/reperfusion
before sustained ischemia (preconditioning), or at the
immediate onset of reperfusion (postconditioning), or in
a remote tissue before, during, or at reperfusion after
sustained myocardial ischemia (remote conditioning).
All forms of conditioning markedly enhance the ability
of the heart to withstand a prolonged ischemic insult
(Fig. 1). The discovery of these endogenous cardiopro-
tective mechanisms has encouraged the exploration of
new ways to protect the ischemic/reperfused myocar-
dium and has amplified our knowledge of the molecular
basis of cell injury and survival mechanisms during
ischemia/reperfusion.
Ischemic heart disease develops as a consequence of
a number of etiologic risk factors predisposing to
atherosclerosis development; it always coexists with
other systemic disease states. These predisposing and/
or coexisting conditions include systemic arterial hy-
pertension with related left ventricular hypertrophy
and disturbed coronary circulation (i.e., hypertensive
heart disease); metabolic diseases, such as hyperlipid-
emia, diabetes mellitus, obesity, insulin resistance, ure-
mia; and heart failure (Heusch et al., 2014). In addition,
aging is a major risk factor predisposing to the de-
velopment of ischemic heart disease. These risk factors
and coexisting conditions exert multiple biochemical ef-
fects on the heart that affect the development of ischemia/
reperfusion injury per se and interfere with responses to
cardioprotective interventions. Moreover, routine drug
therapies for these conditions, e.g., antihyperlipidemic,
antidiabetic, antihypertensive, antianginal, and anti-
platelet drugs, as well as drugs indicated for noncardio-
vascular diseases, may also interfere with cardioprotective
interventions.
Since the original observations of the loss of precon-
ditioning in hyperlipidemic rodents (Szilvassy et al.,
1995; Ferdinandy et al., 1997), it has been well es-
tablished that many of the cardiovascular risk factors
may interfere with cardioprotection by conditioning
strategies (see our earlier reviews: Ferdinandy et al.,
1998, 2007; Ferdinandy, 2003; Ovize et al., 2010).
Nevertheless, most experimental studies on cardiopro-
tection are still undertaken in juvenile healthy animal
models, in which ischemia/reperfusion is imposed in
the absence of the classical risk factors for cardiovas-
cular disease. This has contributed, at least in part, to
the slow progress of translation of preclinical results to
clinical therapy. Although some conditioning treat-
ments in humans have shown promising results, other
studies have shown no cardioprotective effect of con-
ditioning in patients with acute MI (Heusch, 2013).
Therefore, the development of rational therapeutic ap-
proaches to protect the ischemic heart requires pre-
clinical studies that examine cardioprotection specifically
in relation to cardiovascular risk factors and their
medications. Moreover, to avoid unexpected ischemia-
related safety problems, the interaction of drugs with
endogenous cardioprotective mechanisms must be tested
during preclinical and clinical phases of drug develop-
ment as well as in postmarketing clinical studies.
The aim of this review is to update our previous review
(Ferdinandy et al., 2007) on the effects of risk factors on
ischemia/reperfusion injury and cardioprotection and to
emphasize the ongoing critical need for preclinical
studies that model the presence of risk factors and their
pharmacologic treatments. Such studies are required for
the proper validation of molecular targets for cardiopro-
tection, thereby maximizing the chances of success for
translation of cardioprotection into the clinical arena and
for the benefit of the majority of ischemic heart disease
patients who have multiple risk factors and associated
medications. Furthermore, we highlight that routine
medications for cardiovascular and other diseases may
show undesirable effects on endogenous cardioprotective
1144 Ferdinandy et al.
cellular signalingmechanisms, thereby possessing a “hid-
den cardiotoxicity” that may manifest latently in the
ischemic heart as increased sensitivity to ischemic chal-
lenge or a decreased capability to adapt to an ischemic
challenge, i.e., attenuated cardioprotection achieved by
conditioning.
II. Experimental Approaches to Cardioprotection
A. Cardioprotection through Preconditioning
Cardioprotection elicited by ischemic precondition-
ing remains one of the most powerful therapeutic
interventions for limiting infarct size after acute
ischemia/reperfusion injury. Despite ongoing intensive
investigation, the actual mechanisms underlying its
cardioprotective effect and their interaction remain
largely unclear. A large number of signaling pathways
are recruited at the cardiomyocyte sarcolemma through
the activation of cell surface receptors by their endog-
enous ligands. Many of these signal transduction path-
ways appear to terminate at the mitochondria, and it is
in this area where most of the recent research has been
focused (Fig. 2). A comprehensive review of all of the
investigated mechanisms is beyond the scope of this
review. The interested reader is referred to comprehen-
sive reviews published elsewhere on the topics of ischemic
preconditioning and its signal transduction (Heusch et al.,
2008; Hausenloy, 2013).
1. Mitochondria and Preconditioning. Mitochondria ap-
pear to play two critical roles in the setting of ischemic
preconditioning. Before the index ischemic event and in
response to the preconditioning stimulus, mitochondria
are known to release signaling reactive oxygen species
(ROS) that then activate key mediators of cardiopro-
tection, which subsequently prevent the opening of the
mitochondrial permeability transition pore (MPTP) in
the first few minutes of myocardial reperfusion, thereby
attenuating myocardial reperfusion injury and limiting
infarct size.
a. The mitochondrial permeability transition pore
and preconditioning. The mechanism through which
the signaling ROS are generated in response to the
ischemic preconditioning stimulus is not clear, but one
suggestion has implicated the activation of the mito-
chondrial ATP-sensitive potassium channel (KATP),
which is related to mitochondrial connexin 43 (Cx43)
(Heinzel et al., 2005) and appears to be mediated via
protein kinase G (PKG) and mitochondrial protein
kinase C (PKC)« (Costa and Garlid, 2008). The K+
influx into mitochondria is believed to induce matrix
alkalinization that then results in the production of
superoxide from complex I of the electron transport
chain (Soetkamp et al., 2014).
A number of experimental studies have linked is-
chemic preconditioning-induced cardioprotection to the
inhibition of MPTP opening at the onset of reperfusion.
Fig. 1. The concept of ischemia/reperfusion injury and cardioprotection by pre-, post-, and remote conditioning is expressed graphically in the figure,
where black bars denote periods of ischemia. Myocardial ischemia and reperfusion lead to "ischemia/reperfusion injury" characterized by the
development of contractile dysfunction, arrhythmias, and tissue necrosis (infarction). Ischemic preconditioning is a well described acute and subacute
adaptive response in which brief exposure to ischemia/reperfusion markedly enhances the ability of the heart to withstand a subsequent ischemia/
reperfusion injury. In this diagram, three brief periods of ischemia are used to precondition the myocardium against a subsequent period of "test"
ischemia that is longer than the preconditioning periods. Preconditioning induces protection in a biphasic pattern. Brief cycles of ischemia/reperfusion
applied after a longer period of ischemia also confer cardioprotection against the consequences of myocardial ischemia/reperfusion, a phenomenon
called ischemic postconditioning. Brief cycles of ischemia/reperfusion applied in a remote cardiac tissue or remote organ, e.g., kidney, limbs, before,
during, or right after a longer period of cardiac ischemia also provide cardioprotection, a phenomenon called remote conditioning. The cardioprotective
effect of conditioning strategies results in attenuation of ischemia/reperfusion injury characterized by improvement of postischemic contractile
function, decrease in the occurrence and severity of arrhythmias, and reduction of infarct size. Major cardiovascular risk factors and their medications
influence the severity of ischemia/reperfusion injury and interfere with the cardioprotective effect of conditioning.
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The precise mechanism through which this is achieved
remains undetermined but may involve the following:
1) activation of prosurvival pathways, such as the
reperfusion injury salvage kinase (RISK) or survivor
activating factor enhancement (SAFE) signaling path-
ways, that then act to prevent MPTP opening either in
a direct or indirect manner (Hausenloy et al., 2009,
2011). There is evidence to suggest that one particular
downstream mediator, glycogen synthase kinase-3b
(GSK-3b), appears to mediate cardioprotection through
the inhibition of the MPTP, although the mechanism
through which this is achieved is unclear (Juhaszova
et al., 2004); 2) activation of the mitochondrial KATP
channel, which via mitochondrial PKC«, results in
ROS-mediated inhibition of MPTP opening (Costa and
Garlid, 2008); and 3) attenuation of oxidative stress
generated during myocardial ischemia, thereby pre-
venting MPTP opening at reperfusion (Clarke et al.,
2008).
Since 2007, several key developments have arisen
with respect to the MPTP and its role in acute
ischemia/reperfusion injury. Although mitochondrial
cyclophilin D has been established as a regulator of the
MPTP, the precise identities of the components of the
MPTP remain unknown. Recent experimental studies
have suggested that dimers of mitochondrial ATP synthase
may constitute the MPTP (Bonora et al., 2013; Giorgio
et al., 2013). Interestingly, an insight into the potential
physiological role of the MPTP was provided by Elrod
et al. (2010) who reported that mice deficient in mito-
chondrial cyclophilin D were more susceptible to calcium
overload, suggesting that the MPTP may mediate mito-
chondrial calcium efflux, a mechanism that had been
first proposed in 1992 (Altschuld et al., 1992). Another
important discovery was the identity of the mitochondrial
calcium uniporter (Baughman et al., 2011; De Stefani
et al., 2011) and the surprising observation that mice
deficient in the uniporter were not protected from
myocardial infarction despite being resistant to MPTP
opening (Pan et al., 2013).
b. Mitochondrial connexin-43 and preconditioning.
Recent experimental data have suggested that the gap
junction sarcolemmal protein, Cx43, is also present in
cardiac subsarcolemmal inner mitochondrial mem-
branes, where it acts as a signaling mediator of ische-
mic preconditioning but not postconditioning (reviewed
Fig. 2. Mitochondrial reactive oxygen species (ROS, including O2
2, H2O2) are at the center of cardioprotection and/or irreversible injury depending on
the timing and quantity of their generation. Several mitochondrial proteins contribute to the generation of ROS through modulation of proteins of the
respiratory chain (Cx43, STAT3, p66shc) or directly [monoamine oxidases (MAO)]. High amounts of ROS at the time of reperfusion contribute to
irreversible tissue injury, probably by facilitating opening of the mitochondrial permeability transition pore (MPTP). The proteins contributing to the
formation of MPTP are still under investigation, but dimerization of complex V or protein complexes involving adenine-nucleotide transporter (ANT),
hexokinase (HK), and the phosphate carrier (PiC) has been proposed. Many factors apart from ROS are important for MPTP opening, including binding
of cyclophilin-D (CypD), calcium (Ca2+), and ADP. Mitochondrial Ca2+ concentration and homeostasis is influenced by the close interaction with the SR/ER
and specialized proteins for such interaction like mitofusins (Mfn). Under pathophysiological conditions, ADP can be generated by the reversed mode of
complex V using ATP as substrate to maintain the inner mitochondrial membrane proton gradient. ATP will pass the outer mitochondrial membrane
through the voltage-gated anion channel (VDAC) and proteins, such as Bcl2 or Bax, affecting channel open probability. Some other proteins modifying
MPTP opening have been described, such as GSK-3b, aldehyde dehydrogenase 2 (ALDH2), and PKC«. Although high concentrations of ROS are
detrimental, low amounts of ROS can trigger a cardioprotective state and are central to the endogenous protection by pre- and postconditioning. In this
context, increases in mitochondrial potassium (K+) lead to increased ROS formation and are central to endogenous cardioprotection. Here, mitochondrial
KATP but also Cx43 play important roles. Nitrosylation of thiol groups (SNO) are also important for protein activity, and nitric oxide can be derived either
by a mitochondrial nitric oxide synthase (mtNOS) or by a NOS isoform in close proximity to mitochondria, transported by caveolae-like structures into the
mitochondria.
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in Schulz et al., 2007). Cx43 is believed to form hemi-
channels in the inner mitochondrial membrane, there-
by facilitating complex I function and the influx of
K+ into mitochondria in response to the ischemic pre-
conditioning stimulus (Boengler et al., 2012, 2013a;
Soetkamp et al., 2014). The activation of the RISK or
SAFE pathways is not involved in the protective func-
tion of Cx43 in ischemic preconditioning (Sanchez et al.,
2013).
c. Mitochondria and new forms of cell death. The
majority of experimental studies investigating the
beneficial effects of conditioning the heart have focused
on preventing cardiomyocyte death due to necrosis and/or
apoptosis, and in this regard the mitochondria play
a pivotal role. More recently, two further forms of cell
death have been described. Both autophagy (including
mitophagy) and regulated cell necrosis appear to be
relevant to cardiomyocyte death induced by acute
ischemia/reperfusion injury. Only an overview can be
provided here, and the interested reader is referred to
more comprehensive review articles (Giricz et al., 2012;
Kaczmarek et al., 2013).
Autophagy is an evolutionarily conserved process
that mediates the degradation of cytoplasmic compo-
nents via the lysosomal pathway under conditions of
cellular stress. It has been suggested that autophagy
may be an adaptive response to protect the cell against
myocardial ischemia. Autophagy can be activated in
response to ischemic preconditioning, whereas its
activation at the time of reperfusion is thought to be
deleterious (reviewed in Giricz et al., 2012). Mitophagy
allows the removal of defective mitochondria and may
also provide a cardioprotective response (Kubli and
Gustafsson, 2012). This process is initiated by mito-
chondrial fragmentation and mitochondrial membrane
depolarization that induces the translocation of the
cytosolic ubiquitin ligase, parkin, to the mitochondrial
outer membrane where it binds to mitofusin 2, which
in itself has to be phosphorylated by phosphatase and
tensin homologue (PTEN)–induced kinase 1 (Chen and
Dorn, 2013), resulting in the removal of the damaged
mitochondria. Abolishing mitophagy by knockout of
parkin abolishes cardioprotection by ischemic precon-
ditioning (Huang et al., 2011).
Necrosis was previously considered to be an accidental,
unregulated form of cell death. However, there also
appears to be a regulated form of necrotic cell death,
termed "necroptosis" or "programmed necrosis" (reviewed
by Kaczmarek et al., 2013). It is initiated by tumor
necrosis factor a (TNFa) death domain receptor activa-
tion, the receptor-interacting protein 1 and 3 kinases, the
mixed lineage kinase domain-like protein, and mitochon-
drial phosphoglycerate mutase/protein phosphatase,
which then activates dynamin-related protein 1 (Drp1)–
mediated mitochondrial fission resulting in cell death
(Wang et al., 2012). Importantly, pharmacologic inhibi-
tion of this novel death pathway has been reported to
limit infarct size and prevent adverse post-MI left
ventricular remodeling (Lim et al., 2007; Oerlemans
et al., 2012).
d. Mitochondrial dynamics and cardioprotection.
Mitochondria are no longer considered to be static
organelles but are dynamic structures that are able to
change their morphology by undergoing either fusion to
generate elongated mitochondria, which allows replen-
ishment of damaged mitochondrial DNA, or fission to
produce fragmented mitochondria to replace damaged
mitochondria by mitophagy (reviewed in Ong and
Hausenloy, 2010; Ong et al., 2013). Interestingly, car-
diac mitochondria have been demonstrated to undergo
fragmentation during myocardial ischemia under the
control of the mitochondrial fission protein Drp1 (Ong
et al., 2010). Pharmacologic or genetic inhibition of Drp1-
mediated mitochondrial fission induced by ischemia
has been reported to prevent MPTP opening and reduce
infarct size (Ong et al., 2010; Wang et al., 2011a;
Disatnik et al., 2013). Somewhat surprisingly, the
ablation of cardiac mitofusin 1 and 2 (known mitochon-
drial fusion proteins) also prevented MPTP opening and
rendered hearts resistant to acute ischemia/reperfusion
injury (Papanicolaou et al., 2011, 2012). This unexpected
result may be due to the pleiotropic nonfusion effects of
these mitochondrial fusion proteins that include apo-
ptosis induction, mediation of mitophagy, and tethering
the sarcoplasmic reticulum to the mitochondria (de
Brito and Scorrano, 2008a,b; Wang et al., 2012). A
recent study has shown that pharmacologic precondi-
tioning using nitrite protected a cardiac cell line by in-
hibiting ischemia-induced mitochondrial fission through
the activation of protein kinase A (Pride et al., 2014).
Whether ischemic preconditioning and postconditioning
exert their cardioprotective effect by modulating mito-
chondrial morphology is not known.
B. Cardioprotection through Postconditioning
One major limitation of ischemic preconditioning has
been the necessity to apply the therapeutic intervention
before the sustained index myocardial ischemia, the
onset of which is unpredictable in patients presenting
with MI. The discovery in 2003 of ischemic postcondi-
tioning by interrupting myocardial reperfusion with
several cycles of short-lived ischemia has overcome this
limitation (Zhao et al., 2003). The clinical applicability
of ischemic postconditioning was realized only 2 years
later in ST-segment elevated MI (STEMI) patients
treated by percutaneous coronary intervention (PCI)
using reinflation of the coronary angioplasty balloon to
interrupt myocardial reperfusion (Staat et al., 2005) (see
section III for further clinical application of ischemic
postconditioning). The protection afforded by ischemic
postconditioning has been reproduced in most species
tested, although suitable algorithms may be model- and
species-dependent (Skyschally et al., 2009). The modi-
fication of the reperfusion phase had been reported
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previously to confer cardioprotection by more gentle
reperfusion (Musiolik et al., 2010).
In terms of the mechanistic pathway underlying
ischemic postconditioning, many of the signaling path-
ways, but not all (Heusch et al., 2006), are shared with
ischemic preconditioning. Briefly, autacoids activate
prosurvival signal transduction pathways, the majority
of which converge on mitochondria and prevent MPTP
opening at the time of reperfusion. A comprehensive
review of all of the investigated mechanisms is beyond
the scope of this review and we will only focus on the
major developments since 2007. The interested reader
is referred to comprehensive reviews published else-
where on the topics of ischemic postconditioning
(Burley and Baxter, 2009; Ovize et al., 2010; Shi and
Vinten-Johansen, 2012; Hausenloy, 2013).
1. Autacoid Mediators of Postconditioning. Initial
experimental studies using pharmacologic antagonists had
implicated adenosine to be a key mediator of postcondi-
tioning through activation of the adenosine A2A receptor
(Kin et al., 2005), A2B receptor (Philipp et al., 2006), or
A3 receptor (Kin et al., 2005; Philipp et al., 2006), but not the
A1 receptor (Kin et al., 2005; Donato et al., 2007; Xi et al.,
2008). A subsequent study found that mice deficient for
the myocardial adenosine A2A receptor were resistant to
ischemic postconditioning (Morrison et al., 2007). Since
2007, an increasing number of autacoid mediators of
postconditioning have been described, including bradyki-
nin (Penna et al., 2007; Xi et al., 2008), opioids (Jang et al.,
2008; Pateliya et al., 2008; Zatta et al., 2008), TNFa
(Lacerda et al., 2009), and sphingosine (Jin et al., 2008;
Vessey et al., 2008a,b).
2. Delaying the Correction of pH at Reperfusion.
The acidic intracellular conditions produced during
myocardial ischemia exert a strong inhibitory effect on
the MPTP, keeping it closed during ischemia, despite
calcium overload, increased inorganic phosphate, oxida-
tive stress, and ATP depletion. In the first few minutes
of reperfusion, the washout of myocardial lactate and
activation of the Na+-H+ exchanger and Na+-HCO3
2
cotransporter rapidly correct the intracellular acidosis,
thereby releasing the inhibition on the MPTP and
allowing the latter to open at the time of reperfusion
(Halestrap et al., 2004; Yellon and Hausenloy, 2007). A
number of experimental studies reported that ischemic
postconditioning may prevent MPTP opening by delay-
ing the restoration of physiologic pH at the onset of
reperfusion (Cohen et al., 2007; Fujita et al., 2007),
although the actual mechanism through which this
might be achieved is not clear. Whether the stuttering
reperfusion of the postconditioning protocol inhibits
MPTP opening by delaying the washout of the myocar-
dial lactate, attenuating oxidative stress production, or
activating the RISK or SAFE pathway is unclear.
3. Mitochondria and Postconditioning. Experimental
studies suggest that ischemic postconditioning prevents
myocardial reperfusion injury and limits infarct size by
inhibiting MPTP opening (Argaud et al., 2005). As with
ischemic preconditioning, the mechanism through which
this is achieved is not clear, but a number of potential
signaling pathways have been proposed: 1) the acti-
vation of the prosurvival cardioprotective pathways,
such as the RISK, SAFE, and NO-cGMP-PKG path-
ways, at the onset of reperfusion inhibit MPTP opening
(Hausenloy et al., 2005, 2011; Bopassa et al., 2006;
Heusch et al., 2008, 2011; Boengler et al., 2011a;
Andreadou et al., 2014); 2) the delayed restoration in
intracellular pH may inhibit MPTP opening (Cohen
et al., 2007); and 3) the reduction in ROS generated at
reperfusion may prevent MPTP opening (Clarke et al.,
2008).
C. Cardioprotection through Pharmacologic
Conditioning
Elucidation of the signaling pathways underlying
ischemic conditioning in the heart has helped to identify
a number of novel therapeutic targets for cardioprotec-
tion. These include targets in the signal transduction
pathways linking the cell membrane to the mitochondria
and direct targets in the mitochondria. A number of
pharmacologic agents capable of mimicking the cardio-
protective effects of ischemic conditioning continue to be
investigated in the experimental setting, but there ap-
pear to be species differences, e.g., cyclosporine-A does
not protect the rat heart (De Paulis et al., 2013). Some of
these agents have been investigated in the clinical set-
ting already. The most promising pharmacologic car-
dioprotective agents and their potential targets include:
cyclosporine-A (MPTP inhibition); metoprolol, matrix
metalloproteinase (MMP) inhibition, glucagon-like peptide
1 (GLP-1) analogs (RISK pathway); and nitrite/nitrates
and soluble guanylate cyclase activators (NO-cGMP-PKG
pathway) (reviewed in Evgenov et al., 2006; Stasch et al.,
2011; Sharma et al., 2012; Andreadou et al., 2014; Bice
et al., 2014; Rassaf et al., 2014).
D. Cardioprotection through Remote Conditioning
The major disadvantage of ischemic preconditioning
and postconditioning as therapeutic interventions for
limiting acute myocardial ischemia/reperfusion injury is
that they both require the intervention to be applied
directly to the heart, thereby limiting their clinical ap-
plicability. In this regard, the discovery in 1993 (Przyklenk
et al., 1993) that the cardioprotective stimulus could be
applied to remote myocardium and later to a remote
organ away from the heart, was a major advance. This
phenomenon has been termed "remote ischemic condi-
tioning" (reviewed in Hausenloy and Yellon, 2008;
Vinten-Johansen and Shi, 2013). However, the major
breakthrough that facilitated the translation of remote
ischemic conditioning into the clinical setting was the
discovery in the experimental setting that the cardio-
protective stimulus could be applied to the musculo-
skeletal tissue of the hindlimb (Birnbaum et al., 1997;
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Oxman et al., 1997). This was followed by the discovery
in human volunteers that the cardioprotective stimu-
lus could be applied to the arm or leg in a noninvasive
manner by simply inflating and deflating a blood
pressure cuff or similar device (Günaydin et al., 2000;
Kharbanda et al., 2002).
An additional advantage with remote ischemic condi-
tioning is its ability to confer cardioprotection when
initiated at different time points in relation to acute
ischemia/reperfusion injury. It can be applied before
myocardial ischemia (remote ischemic preconditioning)
(Przyklenk et al., 1993); after the onset of myocardial
ischemia but before reperfusion (remote ischemic
perconditioning) (Schmidt et al., 2007); at the onset of
myocardial reperfusion (remote ischemic postcondition-
ing) (Andreka et al., 2007); and even after 15 minutes
of reperfusion has elapsed (remote ischemic delayed
postconditioning) (Basalay et al., 2012). Remote condi-
tioning interventions thereby lend themselves to appli-
cation in a number of different clinical settings of acute
ischemia/reperfusion injury (see section III). Moreover,
repeated daily episodes of remote ischemic postcondi-
tioning over a period of 28 days after MI in a rat model
of acute ischemia/reperfusion injury have been reported
to have beneficial effects on post-MI remodeling (Wei
et al., 2011).
Despite its discovery in 1993, the actual mechanism
underlying the cardioprotective effect of remote condi-
tioning remains unclear. The signal transduction path-
way can be divided into three stages: 1) the application
of the "conditioning" stimulus to the remote organ or
tissue results in the generation of a cardioprotective
signal, the nature of which is unclear; 2) the mechanism
through which the cardioprotective signal is conveyed to
the heart is currently unclear but is believed to involve
both neural and circulating humoral components; and 3)
the recruitment of established cardioprotective signal-
ing pathways within the cardiomyocyte (reviewed in
Hausenloy and Yellon, 2008). Dissection of the indi-
vidual contributions of these three sequential signaling
steps has been an experimental challenge that remains
unsolved. The current paradigm suggests that the
conditioning stimulus within the remote organ or tissue
generates autacoids, such as adenosine, bradykinin, and
opioids, which result in the stimulation of the neural
pathway to that remote organ or tissue (Liem et al.,
2002; Jensen et al., 2012; Redington et al., 2012). The
neural pathway then relays the cardioprotective signal
to the brain stem nuclei (Lonborg et al., 2012), where
a humoral factor(s), as yet unidentified, is released into
the circulation and carried to the heart to mediate the
cardioprotective effect. Recently, involvement of the
SDF-1a/CXCR4 axis has been shown (Davidson et al.,
2013). Also, cardioprotection by remote ischemic pre-
conditioning of the rat heart was recently shown to be
mediated by extracellular vesicles released by brief
periods of ischemia and acting as potential carriers of
cardioprotective substances (Giricz et al., 2014). A
comprehensive discussion of the potential mechanisms
underlying remote ischemic conditioning is beyond the
scope of this review, and the reader is referred to com-
prehensive reviews on the subject (Hausenloy and Yellon,
2008; Vinten-Johansen and Shi, 2013). The clinical ap-
plication of this phenomenon is dealt with in the next
section.
III. Clinical Approaches to Cardioprotection
There are now a number of studies that have ex-
amined cardioprotection by ischemic preconditioning,
ischemic postconditioning, and remote conditioning in
various clinical scenarios (Heusch, 2013).
A. Ischemic Preconditioning
Conceptually, ischemic preconditioning has been as-
sociated with preinfarction angina, i.e., unstable angina
preceding acute MI. It is known that preinfarction
angina is associated with better clinical outcome than
an abrupt acute MI without preceding episodes of angina
(Heusch, 2001; Rezkalla and Kloner, 2004). The causal
attribution of protection with preinfarction angina to
ischemic preconditioning rather than collateral recruit-
ment or more rapid reperfusion, as well as to the early
versus the delayed form of ischemic preconditioning,
remains unclear. Although conceptually inferred for
preinfarction angina, ischemic preconditioning has been
more empirically studied in interventional and surgical
revascularization protocols (Fig. 3).
During repeated balloon angioplasty, ECG altera-
tions, pain sensation, lactate production, and creatine
kinase release were found to be attenuated during the
second compared with the first coronary occlusion
period, and this was taken as evidence of ischemic
preconditioning (Heusch, 2001). With the use of phar-
macologic antagonists, the causal involvement of aden-
osine, opioids, a-adrenoceptor activation, and KATP was
demonstrated. However, a caveat must be noted be-
cause reduced ST-segment elevation can be dissociated
from reduced infarct size (Birincioglu et al., 1999) such
that the selected endpoint of ischemic preconditioning’s
protection may be critical for successful clinical trans-
lation. There are also a number of studies where an
ischemic preconditioning algorithm was used in coro-
nary artery bypass graft or valvular surgery, and pro-
tection was seen in terms of reduced release of serum
biomarkers (creatine kinase-MB, troponin I or T) (Jenkins
et al., 1997; Lu et al., 1997; Szmagala et al., 1998; Li et al.,
1999; Teoh et al., 2002a,b; Buyukates et al., 2005;
Codispoti et al., 2006; Ji et al., 2007; Amr and Yassin,
2010). However, not all studies were positive (Alkhulaifi
et al., 1994; Perrault et al., 1996; Cremer et al., 1997;
Kaukoranta et al., 1997; Illes and Swoyer, 1998; Pêgo-
Fernandes et al., 2000; Wu et al., 2001; Ghosh and
Galinanes, 2003; Jebeli et al., 2010). Both positive and
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negative studies suffer from small cohort sizes and lack of
clinical outcome as endpoint. Nevertheless, the impres-
sion is that ischemic preconditioning can be used to
induce protection in elective cardiac surgery, and a meta-
analysis of published studies suggests clinical benefit in
terms of reduced arrhythmias, less inotrope support
requirement, and reduced intensive care unit stay (Walsh
et al., 2008).
B. Ischemic Postconditioning
Ischemic postconditioning has been used in patients
undergoing primary PCI for an acute MI (Fig. 4). The
landmark study by Staat et al. (2005) appeared only
2 years after the original experimental report of ischemic
postconditioning in dogs (Zhao et al., 2003). Several
studies demonstrated reduced infarct size by reduced
biomarker release (creatine kinase, creatine kinase-
MB, troponin I) or by gadolinium-contrast magnetic
resonance imaging (Ma et al., 2006; Luo et al., 2007;
Yang et al., 2007; Laskey et al., 2008; Luo et al., 2008a,b;
Thibault et al., 2008; Li et al., 2009; Zhao et al., 2009b;
Lonborg et al., 2010; Xue et al., 2010; Garcia et al.,
2011; Ji et al., 2011; Liu et al., 2011a; Luo et al., 2011;
Durdu et al., 2012; Thuny et al., 2012; Liu et al., 2013;
Mewton et al., 2013). However, not all studies have
reported positive findings (Sorensson et al., 2010;
Freixa et al., 2012; Tarantini et al., 2012; Ugata et al.,
2012; Dwyer et al., 2013; Elzbieciak et al., 2013; Hahn
et al., 2013). The sample size of the study cohorts
was small, making them sensitive to false-negative type
II errors. A systematic underestimation of the pro-
tective potential of ischemic postconditioning may
result from lack of direct stenting. Direct stenting
removes any residual stenosis and prevents coronary
microembolization from the culprit lesion (Loubeyre
et al., 2002) when further manipulated by the post-
conditioning maneuver (Heusch, 2012). With use of
direct stenting, the consequences of immediate full
reperfusion are compared with those of a postcondition-
ing algorithm, without any interference by a residual
stenosis or by coronary microembolization. Also, Ovize
and colleagues who consistently reported protection with
ischemic postconditioning always inflated the balloon
upstream of the stent (Staat et al., 2005; Thibault
et al., 2008; Thuny et al., 2012). A larger clinical trial
recently failed to observe reduced peak creatine kinase-
MB or a significant benefit in clinical outcome from
ischemic postconditioning, but unfortunately this trial
did not use direct stenting in most patients (Hahn et al.,
2013).
C. Remote Ischemic Conditioning
In recent years, remote ischemic conditioning has
become the most popular form of mechanical cardiopro-
tection, because the procedure is noninvasive, predict-
able, precise, safe, and notably avoids manipulation of
the coronary culprit lesion (Fig. 5). Remote ischemic
preconditioning has been used in elective interventional
revascularization (Iliodromitis et al., 2006; Hoole et al.,
2009; Ahmed et al., 2013; Luo et al., 2013; Prasad et al.,
Fig. 3. Forest plot on the available clinical studies (state December 2013) on ischemic preconditioning. Gray bars indicate the standard error of the
mean in the placebo group, black bars the % infarct size reduction with its standard error in the conditioned group (updated from Heusch, 2013).
CABG, coronary artery bypass grafting; CK-MB, creatine kinase-MB; IP, ischemic preconditioning; PLA, placebo; TnI, troponin I; TnT, troponin T.
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2013) and in surgical coronary revascularization (Günaydin
et al., 2000; Hausenloy et al., 2007; Venugopal et al.,
2009; Ali et al., 2010; Hong et al., 2010, 2012; Rahman
et al., 2010; Thielmann et al., 2010, 2013; Wagner et al.,
2010; Karuppasamy et al., 2011; Heusch et al., 2012b;
Kottenberg et al., 2012, 2014a; Lomivorotov et al., 2012;
Lucchinetti et al., 2012; Young et al., 2012; Saxena
et al., 2013). The procedure has also been applied in
other forms of cardiac surgery (Cheung et al., 2006; Li
et al., 2010; Zhou et al., 2010; Choi et al., 2011; Luo et al.,
2011; Wu et al., 2011a; Lee et al., 2012; Pavione et al.,
2012; Xie et al., 2012; Young et al., 2012; Albrecht et al.,
2013; Jones et al., 2013; Meybohm et al., 2013; Pepe
et al., 2013). Not all studies reported infarct size reduc-
tion, using biomarker release or imaging as endpoints.
A common feature of all the negative studies appears to
be the use of propofol anesthesia in some form; propofol
has been demonstrated to abrogate the protection by
remote ischemic preconditioning (Kottenberg et al., 2012,
2014a; Bautin et al., 2013).
A few studies have also used a remote conditioning
procedure during an ongoing acute MI before primary
PCI; increased myocardial salvage was seen in one
study (Botker et al., 2010), but no significant reduction
in infarct size by biomarker release or imaging (Botker
et al., 2010; Munk et al., 2010; Rentoukas et al., 2010).
One recent study demonstrated reduced infarct size, as
assessed by biomarker release and magnetic resonance
imaging, when the remote lower limb conditioning
protocol was started in a postconditioning mode at the
onset of reperfusion in patients with acute MI (Crimi
et al., 2013). Three further studies even reported
reduced all-cause mortality (secondary endpoint) in
patients undergoing a remote conditioning protocol
before elective PCI (Davies et al., 2013), emergency PCI
(Sloth et al., 2014), or surgical coronary revasculariza-
tion (Thielmann et al., 2013). Another recent study
reported no clinical benefit in patients undergoing
elective cardiac surgery with a combined remote
ischemic pre- and postconditioning protocol; however,
Fig. 4. Forest plot on the available clinical studies (state December 2013) on ischemic postconditioning. Gray bars indicate the standard error of the mean in
the placebo group, black bars the % infarct size reduction with its standard error in the conditioned group (updated from Heusch, 2013). AMI, acute myocardial
infarction; CABG, coronary artery bypass grafting; CK, creatine kinase; CK-MB, creatine kinase-MB; MRI, magnetic resonance imaging; TnI, troponin I.
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this study also used propofol and did not report
protection in terms of biomarker release or imaging
endpoints (Hong et al., 2014). Also, no additive pro-
tection of local ischemic postconditioning with remote
ischemic preconditioning was seen in the small-scale
RIPOST-MI study in patients undergoing primary PCI
for acute MI (Prunier at al., 2014). We therefore await
the results of several ongoing multicenter trials on
remote conditioning where mortality is a primary end-
point; these include ERICCA (Hausenloy et al., 2012)
(NCT 1247545), RIPHeart (NCT 01067703), or CONDI
II (NCT 01857414).
D. Pharmacologic Postconditioning
Our increasing understanding of the mechanisms
underlying ischemic postconditioning has identified
Fig. 5. Forest plot on the available clinical studies (state December 2013) on remote ischemic conditioning. Gray bars indicate the standard error of the
mean in the placebo group, black bars the % infarct size reduction with its standard error in the conditioned group (updated from Heusch, 2013). AMI,
acute myocardial infarction; CABG, coronary artery bypass grafting; CK, creatine kinase; CK-MB, creatine kinase-MB; MRI, magnetic resonance
imaging; SI, salvage index; TnI, troponin I; TnT, troponin T.
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a vast array of signaling mediators, which can be tar-
geted by pharmacologic agents to recapitulate the car-
dioprotective effects of ischemic postconditioning. In this
regard, a number of pharmacologic approaches to limit
infarct size in STEMI patients undergoing primary PCI
have been investigated (reviewed in Sharma et al., 2012;
Hausenloy et al., 2013a). Unfortunately, many of these
studies have failed to demonstrate any cardioprotective
effect in the clinical setting, despite promising experimen-
tal animal data. This apparent failure can be attributed
to a number of different factors. These include the use of
animal models that do not adequately represent clinical
reality, e.g., due to lack of comorbidities; and poor study
design (Ludman et al., 2010; Ovize et al., 2010; Schwartz-
Longacre et al., 2011; Hausenloy et al., 2010, 2013a; Bell
et al., 2012).
More recently, several novel pharmacologic approaches
have been reported to limit infarct size when adminis-
tered before reperfusion in primary PCI-treated STEMI
patients (Table 1). Most promising among these therapies
are cyclosporine-A, exenatide, and metoprolol. Whether
these pharmacologic postconditioning agents can actually
improve clinical outcomes remains to be investigated,
and in this regard, a large multicenter clinical outcome
study is currently underway investigating cyclosporine-A
(NCT 01502774).
In summary, mechanical and pharmacologic condi-
tioning strategies are promising therapeutic options for
cardioprotection in patients undergoing elective or
emergency coronary revascularization, although there
are several negative studies. Most of the clinical trials,
both positive and negative, have been small. The
positive trials have been conducted in selected patients
under well controlled conditions, whereas the negative
trials (e.g., on remote preconditioning) have been less
selective in terms of patient recruitment and procedures
(anesthesia, surgery). The observed lack of protection in
the negative studies can in part be attributed to the
presence of different risk factors, comorbidities, and
their medications in different patient cohorts, as well as
to poorly validated drug targets in juvenile and healthy
animal models, and poorly designed clinical studies
(Ferdinandy et al., 2007; Ovize et al., 2010; Hausenloy
et al., 2013a). None of the existing studies has really
raised a safety concern for the conditioning strategies.
Larger studies with clinical outcome endpoints are nec-
essary to gain more insight into the clinical applicability
of conditioning strategies in different patient popu-
lations with different medications and confounding
factors.
IV. Effects of Major Risk Factors on Ischemia/
Reperfusion Injury and
Cardioprotective Strategies
In the mid-1990s, hyperlipidemia was the first car-
diovascular risk factor to be associated with the loss of
preconditioning cardioprotection in rabbits and rats
(Szilvassy et al., 1995; Ferdinandy et al., 1997). Since
then, it has been well established that in addition to
hyperlipidemia, most of the other major risk factors
and/or medications that target them may modify cardio-
protective signaling, leading to the loss or attenuation of
cardioprotection by ischemic or pharmacologic condi-
tioning (see for extensive earlier reviews: Ferdinandy
et al., 1998, 2007; Ferdinandy, 2003). In this section, we
review more recent evidence of the impact of the most
important risk factors on ischemia/reperfusion injury
and cardioprotection (Table 2).
A. Aging and Cardioprotection
1. Ischemic/Pharmacologic Preconditioning in Aging.
Although ischemic and pharmacologic preconditioning
attenuate ischemia/reperfusion injury in juvenile hearts,
most studies suggest a loss of protection in aged hearts
(for review, see Ferdinandy et al., 2007; Boengler et al.,
2009; Przyklenk, 2011). By using endothelial function
rather than myocardial infarct size as endpoint of
protection in humans in vivo, increased age was as-
sociated with loss of protection by ischemic precondi-
tioning against endothelial dysfunction after ischemia/
reperfusion in the brachial artery (van den Munckhof
et al., 2013).
A number of studies have focused on different
components of the signaling cascades (for review, see
Heusch et al., 2008), assessing differences between
young and aged hearts that might explain the observed
loss of cardioprotection with aging.
a. Effect of aging on cardioprotective signaling.
i. Cytosolic Signaling. Blockade of the Na+/H+ ex-
changer protected myocardium from ischemia/reperfusion
injury in aged rats, whereas anesthetic preconditioning
did not (Liu and Moore, 2010). cAMP-dependent pro-
tein kinase (PKA) activation and Akt activation are
critical for ischemic preconditioning–induced cardio-
protection (Yang et al., 2013). The adenylyl cyclase
activator forskolin, which promotes subsequent PKA
activation, reduced infarct size in young but not in
aged rat hearts (Huhn et al., 2012). The loss of car-
dioprotection in aged, diabetic Goto-Kakizaki rats was
associated with a chronic upregulation of Akt phos-
phorylation and a lack of further activation of Akt by
ischemic preconditioning (Whittington et al., 2013b).
The myocardial Akt isoforms Akt1 and Akt2 must be
distinguished in their function for ischemic precondi-
tioning’s protection. The lack of a protective response
to ischemic preconditioning in Akt1 knockout mice
was accompanied by impaired phosphorylation (and
thus inactivation) of GSK-3b (Kunuthur et al., 2012).
Similarly, lack of pharmacologic preconditioning by
isoflurane in aged rat hearts was associated with
differences in the Akt/GSK-3b signaling pathway (Zhu
et al., 2010), and pharmacologic GSK-3b inhibition
decreased infarct size in young but not in old rat hearts
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(Zhu et al., 2011a). In aged rat hearts, sirtuin deacetylase-1
(Sirt1) activity was increased after ischemia/reperfusion
compared with young hearts (Adam et al., 2013). Al-
though young Sirt1 knockout mice hearts could not be
preconditioned (Nadtochiy et al., 2011b), a drug-induced
increase in Sirt1 activity did not elicit cardioprotection
after ischemia/reperfusion, suggesting that Sirt1 activity
is necessary but not sufficient for the cardioprotective
effects of ischemic preconditioning (Nadtochiy et al.,
2011a) and is most likely not responsible for any observed
age-related difference.
ii. Mitochondria. The different cytosolic signaling
pathways activated by ischemic or pharmacologic
preconditioning converge at the level of mitochondria
(for review, see Heusch et al., 2008; Boengler et al.,
2011a,b; Wojtovich et al., 2012), and the opening of
certain mitochondrial ion channels alone is sufficient to
elicit protection (for review, see Wojtovich et al., 2012).
Pharmacologic preconditioning by helium, which pro-
tected young but not old rat hearts, could be abolished
by blockade of the mitochondrial calcium-sensitive
potassium channel (Heinen et al., 2008). As expected,
pharmacologic activation of the mitochondrial calcium-
sensitive potassium channel reduced irreversible in-
jury induced by ischemia/reperfusion in young rat hearts
but surprisingly was also effective in reducing infarct
size in aged rat hearts (Huhn et al., 2012). GSK-3b
inhibition significantly prolonged the time to MPTP
opening induced by ROS in cardiomyocytes isolated
from young but not from aged rat hearts (Zhu et al.,
2011a, 2013b). Attenuation of ischemic or pharmaco-
logic preconditioning’s protection in the aged heart was
associated with failure to reduce adenine-nucleotide-
translocase-cyclophilin-D interactions, a critical modu-
lator of MPTP opening (Zhu et al., 2013b). Cyclosporine
A, which binds cyclophilin D, thereby delaying MPTP
opening, reduced myocardial infarct size and time to
MPTP opening in young rats, whereas it failed to
significantly affect either infarct size or time to MPTP
opening in old rats (Liu et al., 2011b). Four weeks of
treatment with the superoxide scavenger tempol re-
stored pharmacologic preconditioning and cardio-
protection by cyclosporine-A in old rats, and the
reinstatement of the cardioprotected condition was as-
sociated with delayed onset of MPTP opening (Zhu
et al., 2013a).
TABLE 1
Clinical studies of PPCI-treated STEMI patients who reported beneficial effects with a pharmacologic agent administered at early reperfusion
Clinical Study Pharmacologic Postconditioning Agent Number ofPatients Effect Mechanism of Cardioprotection
Atrial natriuretic peptide
J-WIND-ANP
(Kitakaze et al., 2007)
Intravenous carperitide 72-hour
infusion started after
reperfusion
569 15% reduction in infarct size
(72-hour AUC total CK)
Atrial natriuretic peptide is
a pharmacologic activator of
a number of prosurvival
signaling pathways including
the RISK and cGMP-PKG
pathways.
2.0% absolute increase in left
ventricular ejection fraction
Cyclosporin A
Piot et al., 2008 Intravenous CsA (2.5 mg/kg) 10
minutes before primary PCI
58 44% reduction in infarct size
(72-hour AUC total CK)
Cyclosporin-A is a known
inhibitor of the mitochondrial
permeability transition pore,
a critical determinant of
cardiomyocyte death.
20% reduction in infarct size
(CMR in subset of 27 patients)
28% reduction in infarct size and
smaller LVESV on CMR at
6 months (Mewton et al., 2010)
Exenatide
Lonborg et al., 2012 Intravenous infusion of exenatide
started 15 minutes before
primary PCI for 6 hours
107 Increase in myocardial salvage
index at 90 days by CMR
Exenatide is a long-acting analog
of GLP-1 that lowers blood
glucose as well as limiting MI
size through the activation of
the RISK pathway.
Reduced infarct size as % of AAR
at 90 days by CMR
Patients presenting with short
ischemic times (# 132 min) had
greater myocardial salvage
Glucose insulin potassium (GIK)
therapy
IMMEDIATE
(Selker et al., 2012)
Intravenous GIK infusion for 12
hours started by paramedics in
ambulance before reperfusion
357 Reduction in infarct size and less
in-hospital mortality and
cardiac arrest
GIK promotes glucose
metabolism during myocardial
ischemia that has beneficial
effects on cellular function.
Metoprolol
METOCARD-CNIC 2013
(Ibanez et al., 2013)
Intravenous metoprolol 3–5 mg
boluses administered in
ambulance before PPCI.
220 20% reduction in infarct size
(5–7 days by CMR)
Metoprolol reduces myocardial
oxygen consumption and may
have direct cardioprotective
effects on the cardiomyocyte.
AAR, area at risk measured; AUC, area under the curve; CK, creatinine kinase; CMR, cardiac MRI; LVESV, left ventricular end-systolic volume.
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b. Sex paradox. Most of the experimental studies (for
review, see Ostadal et al., 2009) confirm the clinical
observations (Canali et al., 2012) that female hearts have
an increased resistance to ischemia/reperfusion injury,
associated with an altered distribution of PKC and ex-
tracellular signal-regulated kinase (ERK) isoforms com-
pared with male hearts (Hunter and Korzick, 2005). The
already high tolerance of the adult female heart can be
increased further by ischemic preconditioning. However,
it seems that this protective effect of preconditioning in
female animals depends on age: it was absent in the
young female rat heart but it appeared with the decrease
of resistance toward ischemia/reperfusion injury during
aging (Ostadal et al., 2009). An increased resistance
toward ischemia/reperfusion injury in aged female hearts
could also be restored by a PKC«-activator administered
before ischemia, and restoration of protection was associ-
ated with an enhanced mitochondrial PKC«-translocation
(Lancaster et al., 2011).
c. Delayed preconditioning (second window of
protection). Twenty-four hour delayed anesthetic pre-
conditioning with sevoflurane reduced infarct size in
young but not in old rat hearts. Anesthetic precondi-
tioning affected gene expression profiles (functional
categories of cell defense/death, cell structure, gene
expression/protein synthesis, inflammatory response/
growth/remodeling, and signaling/communication) of
the cardiomyocyte in an age-associated pattern (Zhong
et al., 2012).
2. Aging and Ischemic andPharmacologic Postconditioning.
Ischemic or pharmacologic postconditioning attenu-
ates ischemia/reperfusion injury in young animal hearts
(Skyschally et al., 2009). However, in most, although
not all (Yin et al., 2009) studies, the protection is lost
in aged hearts (for review, see Boengler et al., 2009;
Przyklenk et al., 2011). Comparing ischemic precondi-
tioning and postconditioning, one study suggested that
ischemic postconditioning was less affected by aging
than ischemic preconditioning (Vessey et al., 2009). How-
ever, genetic characteristics, a minor difference in age, or
the number of postconditioning cycles are all critical
factors for the successful effect of ischemic postcondi-
tioning and must be taken into consideration (Boengler
et al., 2008a, 2009; Skyschally et al., 2009; Somers et al.,
2011). Although there is no doubt that postconditioning
protects human hearts (Heusch et al., 2013), there is
some evidence that the extent of protection might
depend on age. In a retrospective analysis, postcon-
ditioning the human heart by multiple balloon in-
flations failed to reduce irreversible injury in patients
above the age of 65 years (Darling et al., 2007). By
using the improvement of left ventricular function
by postconditioning as endpoint, rather than re-
duction of infarct size, a recent meta-analysis also
suggested a beneficial effect of postconditioning only
in patients younger than 62 years (Zhou et al.,
2012).
As with ischemic preconditioning, the more recent
experimental studies have attempted to define specific
alterations in the signaling mechanisms leading to the
failure of protection by postconditioning in aged com-
pared with young hearts.
a. Cytosolic signaling. Ischemic postconditioning
reduced infarct size in young mice hearts, and the
protection was associated with an upregulation of ERK
but not Akt signaling. In contrast, postconditioning
failed to limit infarct size in aged hearts, possibly as
a consequence of the defect in ERK phosphorylation
and increased mitogen activated protein kinase
phosphatase-1 expression. Indeed, mitogen activated
protein kinase phosphatase inhibition restored the is-
chemic postconditioned phenotype in aged mice hearts
(Przyklenk et al., 2008). Similarly, pharmacologic
postconditioning with isoflurane protected the heart
in young but not in senescent rats; again the failure to
activate the RISK pathway might have contributed
to the attenuation of isoflurane-induced postcondition-
ing effect in senescent rats (Chang et al., 2012). In one
study with maintained reduction of infarct size by
ischemic postconditioning in aged rat hearts (16–18
months), protection was accompanied by an increase in
phosphorylation of Akt and GSK-3b similar to that
measured in young rat hearts (Yin et al., 2009). In
addition to the RISK pathway, the SAFE pathway also
appears to be affected by age. The signal transducer
and activator of transcription-3 (STAT3), which is
involved in ischemia/reperfusion injury and cardiopro-
tection by conditioning protocols (Boengler et al.,
2008b), was less highly expressed and activated in aged
mice hearts (Boengler et al., 2008a). Possibly, STAT3
plays a role in modifying mitochondrial function during
ischemia/reperfusion, such as ROS formation (Boengler
TABLE 2
Effect of major risk factors on ischemia/reperfusion (I/R) injury as well as pre-, post-, and remote conditioning in the majority of
the studies
Risk Factor I/R Injury Preconditioning Postconditioning Remote Conditioning
Aging ↑ ↓ ↓ — CL
Hypertension, hypertrophy, and remodeling — — ↓ N.D.
Hyperlipidemia ↑ ↓ CL ↓ N.D.
Diabetes ↑ ↓ CL ↓ ↓CL
Uremia, kidney failure ↑ — — N.D.
Impaired coronary microcirculation ↑ —↑ ↓ N.D.
CL, some clinical data are also available; N.D., no data available; ↑, enhance; ↓, attenuate, —, no effect.
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et al., 2013b) and opening of the MPTP (Boengler et al.,
2010; Heusch et al., 2011). Although many postcondi-
tioning interventions are affected by age, pharmacologic
postconditioning with sphingosine reduced infarct size to
the same extent in young and aged rat hearts (Vessey
et al., 2009). Blockade of PKG or PKA attenuated the
cardioprotection by sphingosine, suggesting that the
cyclic nucleotide-dependent signaling pathway utilized
by sphingosine remains unaffected by age (Vessey et al.,
2008a,b, 2009).
b. Mitochondria. Similarly to what has been de-
scribed for ischemic preconditioning, direct pharmaco-
logic inhibition of electron transport at reperfusion
using amobarbital protected mitochondria and de-
creased myocardial injury in isolated aged rat hearts,
even when signaling-induced pathways of postcondi-
tioning that are upstream of mitochondria were in-
effective (Chen et al., 2012).
3. Aging and Remote Ischemic Preconditioning.
Although remote ischemic preconditioning protects young
and aged human hearts from ischemia/reperfusion-
induced irreversible injury and improves patient out-
comes after coronary artery bypass grafting, little is
known about the age dependency of the process. In
a recent experimental study, remote ischemic precondi-
tioning by lower limb ischemia did not protect against
ischemia/reperfusion injury in isolated newborn rabbit
hearts and even caused deleterious effects in these hearts,
although it effectively reduced infarct size in adult rabbit
hearts (Schmidt et al., 2014).
Using endothelial function rather than irreversible
myocardial injury as endpoint, healthy elderly people
had a greater relative increase of flow-mediated vasodi-
latation after remote ischemic preconditioning than
young individuals (Moro et al., 2011). Thus, whether an
age dependency of remote ischemic preconditioning exists
remains unknown at present.
Taken together, many studies demonstrate that
protection by ischemic and pharmacologic precondition-
ing (early and delayed phase) and postconditioning is
lost in aged hearts. Loss of cardioprotection is related to
alterations in cytosolic signaling cascades leading to
modification in the opening of MPTP. However, direct
stimulation of mitochondrial targets might be capable of
inducing protection even in aged hearts.
B. Hypertension, Cardiac Hypertrophy,
and Remodeling
Ischemic or pharmacologic (e.g., adenosine-receptor
agonist, propofol) preconditioning reduced infarct size
in normotensive and hypertensive, hypertrophied rat
hearts in vitro (Ebrahim et al., 2007; Hochhauser et al.,
2007; King et al., 2012) and in vivo (Dai et al., 2009).
Similarly, pharmacologic preconditioning with isoflurane
6 weeks after permanent coronary artery ligation re-
duced infarct size after ischemia/reperfusion in the re-
maining myocardium, although hearts exhibited a
substantial compensatory hypertrophy. The cardiopro-
tection by isoflurane was abolished by inhibition of
phosphatidylinositol 3-kinase (PI3K) or KATP blockade,
indicating that the established signaling cascade of
protection was intact in the remodeled myocardium
(Lucchinetti et al., 2008). In contrast, ischemic post-
conditioning reduced infarct size in normotensive but
not hypertensive rat hearts (Penna et al., 2010; Wagner
et al., 2013). The phosphorylation of GSK-3b was
increased by ischemic postconditioning in normotensive
rats. However, this increase was completely absent in
hypertensive, hypertrophied rat hearts (Wagner et al.,
2013). In anabolic steroid-induced cardiac hypertrophy,
ischemic postconditioning failed to reduce infarct size
after ischemia/reperfusion; postconditioning increased
Akt phosphorylation regardless of its protective effects,
but reduced expression of protein phosphatase expres-
sion was measured in protected hearts (Penna et al.,
2011). Chronic captopril treatment significantly reduced
left ventricular hypertrophy in hypertensive rats and
reduced infarct size after ischemia/reperfusion in
isolated hearts from both normotensive and hyperten-
sive rats. Ischemic postconditioning was unable to add
its protective effect to that of chronic captopril although
treatment induced hypertrophy regression and almost
completely normalized left ventricular pressure (Penna
et al., 2010).
Taken together, although preconditioning’s protection
is still present in animals with hypertension and/or
left ventricular hypertrophy, infarct size reduction by
ischemic postconditioning appears to be lost. Once again
the lack of protection by ischemic postconditioning
relates to changes in the cytosolic signaling pathway.
Treatment of the primary disease (hypertension, hyper-
trophy) does not restore the cardioprotection by ischemic
postconditioning.
C. Hyperlipidemia and Atherosclerosis
1. Ischemia/Reperfusion Injury, Ischemic Pre-, Post-,
and Remote Conditioning in Hyperlipidemia. In epi-
demiological studies, there is a well recognized relation-
ship between serum total cholesterol concentration and
the morbidity and mortality due to MI. Previously, this
was attributed solely to the development of coronary
atherosclerosis as a result of hypercholesterolemia. How-
ever, in the last two decades, a significant volume of
evidence has accumulated showing that hyperlipidemia
exerts direct effects on the myocardium that may inter-
fere with cardioprotective mechanisms. Although there
are some conflicting results, most of the preclinical studies,
together with some small scale clinical studies, have
shown that hyperlipidemia per se, but not atheroscle-
rosis, leads to a significant aggravation of myocardial
ischemia/reperfusion injury and to attenuation of the
cardioprotective effect of both early and late precondi-
tioning. These studies were reviewed by us previously
(Ferdinandy et al., 2007).
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More recent studies confirm the deleterious effects of
hyperlipidemia on susceptibility to ischemia/reperfusion
injury and on ischemic preconditioning. Expansion of
infarct size in a hyperlipidemic pig model was shown by
Osipov et al. (2009). The loss of the infarct size limiting
effect of ischemic preconditioning (Gorbe et al., 2011;
Landim et al., 2013; Babbar et al., 2013; Yadav et al.,
2010b; Xu et al., 2013) and late ischemic preconditioning
(Yadav et al., 2012) have been shown in different models
of diet-induced hyperlipidemia in rats.
The loss of the infarct size limiting effect of ischemic
postconditioning has been also confirmed in the last
5 years by several studies in hypercholesterolemic rat
(Kupai et al., 2009; Landim et al., 2013; Wu et al., 2014)
and rabbit models (Andreadou et al., 2012; Iliodromitis
et al., 2010). In the fructose-fed hypertriglyceridemic
rat heart, cholesterol lowering by fenofibrate re-
stored ischemic preconditioning-mediated cardiopro-
tection (Babbar et al., 2013). However, in one study
ischemic postconditioning was still effective in hyper-
lipidemic rats (Zhao et al., 2009a). The effect of hy-
perlipidemia on remote conditioning has not yet been
reported.
2. Pharmacologic Cardioprotection in Hyperlipid-
emia: Implications for Target Validation. One of the
most extensively investigated cardioprotective cellular
signaling pathways is the NO-cGMP-PKG pathway, and
elements of this signaling pathway are thought to be
promising drug targets (Burley et al., 2007; Garcia-
Dorado et al., 2009; Gorbe et al., 2010; Andreadou et al.,
2014; Bice et al., 2014). However, Giricz et al. (2009)
showed that, although the NO donor SNAP, which
activates soluble guanylate cyclase, or BNP, which
activates particulate guanylate cyclase, or the stable
cGMP analog 8-bromo cGMP, significantly reduced
infarct size in normal rat hearts, none of these treat-
ments was effective in hearts of rats fed a cholesterol-
enriched diet. The loss of cardioprotection by activators
of the cGMP-PKG pathway was possibly due to in-
activation of PKG by oxidative dimerization of the
kinase under hyperlipidemic conditions. These results
indicate that drug targets upstream of PKG are less
likely targets for cardioprotection, because activation of
such targets does not provide cardioprotection in the
presence of hyperlipidemia. Another recognized cardio-
protective pathway includes KATP channel activation.
However, it was recently shown that the infarct size
limiting effect of either the nonselective KATP activator
cromakalim or the selective mitochondrial KATP activator
diazoxide was abrogated in hyperlipidemic, cholesterol-
fed rats (Csonka et al., 2014). Sevoflurane-induced
delayed cardioprotection against ischemia/reperfusion
injury was also lost in hypercholesterolemia, potentially
via interference of hyperlipidemia with the inducible
NO synthase/mitochondrial KATP channel pathway in
rats (Zhang et al., 2012). Moreover, in hyperlipidemic
Zucker obese rats, neither postconditioning nor the
MPTP inhibitor cyclosporine-A could exert cardiopro-
tection (Huhn et al., 2010). These results indicate that
activation of the NO-cGMP-PKG pathway or KATP
channels and inhibition of the MPTP may not be ideal
cardioprotective drug targets, because they are in-
effective in the presence of hyperlipidemia, a frequent
attendant condition in patients with ischemic heart
disease.
In contrast, the use of hyperlipidemic animal models
of cardioprotection reveals some pharmacologic targets
that remain effective in the presence of hyperlipidemia.
Cardioprotection by preconditioning involves an ap-
proximately 20% inhibition of myocardial MMP2 (Lalu
et al., 2002; Giricz et al., 2006). However, MMP2 in-
hibition by preconditioning is absent in hyperlipidemic
rats. Giricz et al. (2006) showed that by mimicking the
moderate MMP2 inhibitory effect of preconditioning
with the inhibitor ilomastat, cardioprotection occurred
in both normal and hyperlipidemic hearts. Effective
cardioprotection by a moderate inhibition of intracel-
lular MMP2 was confirmed recently by Bencsik et al.
(2014). MMP2 inhibition as a pathway parallel to the
known cardioprotective pathways has been confirmed
by Bell et al. (2013). Dietary supplementation of red
palm oil in rats with established hyperlipidemia was
able to reduce infarct size associated with MMP2
inhibition (Szucs et al., 2011). These results show that
MMP2 inhibition might be a valid cardioprotective
target, because moderate inhibition of MMP2 in the
heart confers cardioprotection in both normal and
hyperlipidemic animals subjected to MI (Dorman
et al., 2010). Independent of MMP2 inhibition, Yadav
et al. (2012) showed that pharmacologic inhibition of
GSK-3b produced a late cardioprotected state in both
normal and hyperlipidemic rats, possibly associated
with 72 kDa heat shock protein induction. This may
also suggest an MPTP-independent effect of GSK-3b
inhibition.
3. Effect of Hyperlipidemia on Cardioprotective
Cellular Mechanisms. The mechanism by which hy-
perlipidemia may influence the severity of myocardial
ischemia/reperfusion injury and cardioprotection is
not fully understood. However, decreased cardiac NO
content, increased oxidative/nitrosative stress, inacti-
vation of PKG, impairment of the mevalonate pathway,
decreased heat-shock response, increased ecto-59-
nucleotidase activity, enhanced apoptotic cell death, as
well as dramatic changes in cardiac gene expression
profile, have all been demonstrated as consequences of
hyperlipidemia (see for earlier reviews: Ferdinandy
et al., 1998, 2007; Ferdinandy, 2003). Moreover, there
is evidence that the microRNA expression pattern of
hyperlipidemic rat hearts (Varga et al., 2013) and the
gene expression patterns in the Zucker Diabetic Fatty
rat strain are changed (Sarkozy et al., 2013), indicating
that the heart responds to the systemic hyperlipidemic
state by concerted alterations in gene expression
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including genes controlling metabolic functions. We
also showed that hyperlipidemia changes Cx43 distri-
bution in the sarcolemma and in the mitochondria
(Gorbe et al., 2011). Hyperlipidemia also interferes
with the nitrosative triggering signal of postcondition-
ing in rats (Kupai et al., 2009)
In summary, the majority of preclinical studies show
that hyperlipidemia worsens the outcome of ischemia/
reperfusion injury and attenuates the cardioprotective
effect of both early and late preconditioning, postcondition-
ing, and pharmacologic conditioning via hyperlipidemia-
induced changes in cardioprotective signaling pathways.
Nevertheless, there are some promising targets that may
be still effective in the hyperlipidemic heart, e.g., MMP-2.
These findings emphasize the necessity for the develop-
ment of new cardioprotective drugs that are able to reverse
the increased susceptibility of hyperlipidemic hearts to
ischemia/reperfusion stress and to enhance adaptive car-
dioprotective mechanisms in hyperlipidemic patients.
D. Diabetes
Epidemiological studies and clinical trials have
clearly shown that both type I (insulin-dependent)
and type II (noninsulin-dependent) diabetics are more
prone to developing ischemic heart disease, including
acute MI and post-MI complications (Otto et al., 2012;
Baars et al., 2013). The diabetic heart is more susceptible
to acute myocardial ischemia/reperfusion injury (Alegria
et al., 2007; Marso et al., 2007).
1. Ischemia/Reperfusion Injury in Diabetes.
Although it has long been known that diabetes is an
independent risk factor for the development of ischemic
heart disease and that the long-term outcome of ische-
mic heart disease is worsened by diabetes in humans,
inconsistency exists in the literature regarding the sus-
ceptibility of myocardium to acute ischemia/reperfusion
injury in various animal models of diabetes (reviewed
in Ferdinandy et al., 2007; Miki et al., 2012; Whittington
et al., 2012). With respect to the preclinical animal
studies, it appears that the susceptibility of the diabetic
heart to acute ischemia/reperfusion injury is critically
dependent on the duration and severity of the diabetes
model and the experimental conditions of the acute
ischemia/reperfusion injury model.
In experimental studies, the diabetic heart has been
shown to be less sensitive to acute ischemia/reperfusion
injury in those experimental studies that used 1) a short
duration of diabetes (,6 weeks); 2) glucose as the only
substrate; and 3) a no-flow acute ischemia/reperfusion
injury protocol. In contrast, in studies where the
diabetes model was more prolonged and severe, fatty
acids were present in the substrate, and a low-flow
acute ischemia/reperfusion injury protocol was used, the
diabetic heart was found to be more sensitive to acute
ischemia/reperfusion injury (Miki et al., 2012; Whittington
et al., 2012). In contrast to the inconsistent preclinical
studies, the majority of clinical studies demonstrates
worse outcome from acute MI in diabetic patients.
This suggests that the use of chronic diabetes animal
models better reflects the clinical situation.
A number of studies have examined cardioprotection
in different experimental animal models of diabetes
and in diabetic patients. The majority of studies shows
that the presence of diabetes may interfere with the
cardioprotective mechanisms, attenuating the effec-
tiveness of these therapeutic strategies. As expected in
some of the animal diabetic models used in the
experimental studies, there is some overlap with the
related comorbidities of obesity and metabolic syn-
drome, both of which may also impact on the efficacy of
cardioprotection. Many of the therapies used to treat
diabetes may also impact on the cardioprotective
intervention (discussed in a later section V.C). Finally,
some experimental studies are beginning to investigate
the effect of one or more comorbidities on the efficacy of
cardioprotective strategies, which better reflects the
clinical setting in which multiple comorbidities often
coexist with ischemic heart disease.
2. Cardioprotection by Preconditioning in Diabetes.
The majority of preclinical experimental studies in-
vestigating the effect of diabetes on the myocardial
response to either ischemic or pharmacologic precondi-
tioning has found that the presence of diabetes renders
the heart more resistant to the infarct size–limiting
effects of preconditioning (reviewed in Ferdinandy
et al., 2007; Miki et al., 2012). Recent experimental
studies have also shown that the cardioprotective
efficacy of pharmacologic preconditioning using a vari-
ety of different agents, including erythropoietin (Miki
et al., 2009; Hotta et al., 2010), d-opioid receptor agonist
(Hotta et al., 2010), isoflurane (Matsumoto et al., 2009),
L-glutamate (Povlsen et al., 2009), remifentanil (Kim
et al., 2010), and helium (Huhn et al., 2009b), is also
impaired in the diabetic heart. Whittington et al.
(2013b) investigated the combined effect of diabetes
and age on the response of the heart to acute ischemia/
reperfusion injury. As expected, the combination
of aging (up to 18 months in the rat) and diabetes
(Goto-Kaziaki rat) increased infarct size in response
to acute ischemia/reperfusion and raised the threshold
for ischemic preconditioning in a predictably additive
manner.
a. Mechanisms contributing to resistance of the
diabetic heart to preconditioning. A variety of differ-
ent mechanisms have been suggested to contribute to
the impaired response of the diabetic heart to precondi-
tioning. These include impaired activation of known
intracellular prosurvival signaling pathways, such as
the Akt and ERK1/2 components of the RISK pathway
(Hausenloy and Yellon, 2007), and its downstream tar-
gets, such as GSK-3b and the Janus-activated kinase-
STAT3 components of the SAFE pathway (Lecour,
2009). More recent experimental studies have investigated
the effect of chronic Akt activation on the myocardial
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response to preconditioning. Whittington et al. (2013b)
found that in the aged rat heart (12–18 months old)
there was chronic activation of Akt, which was not
further augmented in response to ischemic precondi-
tioning, suggesting that in this setting Akt activation
may not mediate cardioprotection. In this regard,
Fullmer et al. (2013) showed that pharmacologic
(insulin) or genetic activation of Akt in the heart
blocked the infarct size–limiting effects of ischemic
preconditioning.
Since 2007, experimental studies have investigated
several novel mechanisms to explain the impaired
response of the diabetic heart to preconditioning. Miki
et al. (2009) reported that the presence of augmented
endoplasmic reticulum stress in the diabetic heart
blocked ERK1/2-mediated phosphorylation of GSK-3b,
leading to increased susceptibility to MPTP opening and
mitochondrial calcium overload. Hotta et al. (2010)
showed that the angiotensin II subtype 1 receptor–
mediated upregulation of calcineurin in the diabetic rat
heart interfered with the phosphorylation of Janus-
activated kinase 2 and PI3K-Akt signaling, thereby
affecting the efficacy of pharmacologic preconditioning.
Ajmani et al. (2011) provided data implicating caveolin,
which was increased in the diabetic heart and interfered
with endothelial NO synthase (eNOS) activity, contrib-
uting to the inability of the diabetic heart to respond
to ischemic preconditioning. Impaired mitochondrial
biogenesis, secondary to a dysfunctional adiponectin-
adenosine monophosphate–activated kinase (AMPK) axis
(Yan et al., 2013), and increased TNFa-induced oxidative
stress (Su et al., 2013) were also proposed as mechanisms
underlying the greater sensitivity of the diabetic heart to
ischemia/reperfusion injury and its resistance to ischemic
preconditioning. A recent study by Gurel et al. (2013)
provided preliminary data suggesting that in the diabetic
heart the failure of ischemic preconditioning to localize
hexokinase to mitochondria may contribute to the lack of
cardioprotection. Finally, an intriguing study by Vinokur
et al. (2013) suggests that altered iron metabolism may
contribute to the response of the diabetic heart to acute
ischemia/reperfusion injury and ischemic precondition-
ing. Under basal conditions diabetic hearts sustained less
acute ischemia/reperfusion injury, a finding that was
associated with basally increased levels of myocardial
ferritin, a cardioprotective factor. Conversely, the failure
of the diabetic heart to respond to ischemic precondition-
ing was found to be associated with an accelerated loss of
myocardial ferritin during ischemia.
To overcome the resistance of the diabetic heart to
preconditioning, several studies have used pharmaco-
logic agents to target the effectors of cardioprotection
downstream of the impaired signaling pathways or
have used pharmacologic modulation of alternative
cardioprotective pathways. In this regard, it has been
shown that pharmacologic inhibition of GSK-3b, a
downstream target of Akt and ERK1/2, was able to
reduce infarct size in the diabetic heart (Miki et al.,
2009; Yadav et al., 2010a). Other experimental studies
have reported being able to pharmacologically pre-
condition the diabetic heart using a variety of diverse
agents including olprinone (a phosphodiesterase type 3
inhibitor) (Matsumoto et al., 2009) and even ginseno-
side Rb1 (a pharmacologically active component of
ginseng) (Wu et al., 2011b).
b. Restoring myocardial sensitivity to preconditioning
in the presence of diabetes. Whether antidiabetic
therapy or another pharmacologic agent can restore
the sensitivity of the diabetic heart to preconditioning
has been investigated. Gu et al. (2008) found that
simvastatin treatment was able to restore cardioprotec-
tion elicited by ischemic preconditioning in the pres-
ence of hyperglycemia, and this effect was associated
with the generation of NO. Pretreatment of diabetic
Goto-Kakizaki rats with the antidiabetic sulfonylurea
glimepiride (which did not reduce infarct size itself) was
demonstrated to restore the sensitivity of the myocar-
dium to ischemic preconditioning, such that one cycle
instead of three cycles of ischemic preconditioning was
sufficient to limit infarct size (Hausenloy et al., 2013c).
However, this effect of glimepiride in lowering the thresh-
old for ischemic preconditioning appeared to be indepen-
dent of serum glucose levels, because the latter remained
unchanged with glimepiride treatment (Hausenloy et al.,
2013c). Finally, chronic insulin treatment increases car-
diac adiponectin and restores cardioprotective AMPK sig-
naling (Pei et al., 2013).
Experimental studies using human right atrial
tissue harvested from patients undergoing coronary
artery bypass grafting surgery have reported that
myocardial tissue from diabetic patients is resistant to
ischemic preconditioning when subjected to simulated
acute ischemia/reperfusion injury (Ovunc, 2000; Barua
et al., 2011). Barua et al. (2011) showed that the
resistance to ischemic preconditioning could be over-
come by modulating NO availability in atrial tissue
from diabetic patients. Interestingly, Sivaraman et al.
(2010) demonstrated that intensifying the ischemic
preconditioning stimulus protected isolated human
right atrial trabeculae harvested from diabetic patients
against simulated acute ischemia/reperfusion injury.
In this study, the inability to precondition the diabetic
atrial tissue using a standard preconditioning protocol
was associated with lower basal levels of Akt activation
(Sivaraman et al., 2010). Furthermore, Wang et al.
(2011b) reported enhanced expression of PTEN (a sup-
pressor of Akt activity) through microRNA interference
(Ling et al., 2013) associated with reduced Akt and
downstream eNOS expression in diabetic human atrial
tissue.
In vivo human data have confirmed the resistance of
diabetic patients to the protective effect of ischemic
preconditioning. Engbersen et al. (2012) demonstrated
using a forearm model of endothelial injury that the
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efficacy of ischemic preconditioning to reduce acute
ischemia/reperfusion injury was lower in type 1 di-
abetic patients and was completely abolished in these
patients during hyperglycemia.
3. Cardioprotection by Postconditioning in Diabetes
andMetabolic Syndrome. Experimental animal data sug-
gest that the presence of diabetes and related conditions,
such as obesity and metabolic syndrome, may impact
on the cardioprotective efficacy of both ischemic and
pharmacologic postconditioning. For ischemic postcon-
ditioning, using either a genetic or a chemically induced
murine model of diabetes, Przyklenk et al. (2011) found
that the isolated perfused diabetic heart was resistant
to the infarct size–limiting effects of ischemic postcon-
ditioning compared with the normoglycemic heart. In
this study, the lack of response to ischemic postcondi-
tioning in the diabetic heart was associated with
a failure to activate the ERK1/2 component of the RISK
pathway. By using an isolated rat heart model of acute
ischemia/reperfusion injury, Ren et al. (2011) demon-
strated that the failure to postcondition the diabetic
heart appeared to be linked to reduced myocardial
expression of transient receptor potential vanilloid 1
channel, calcitonin gene related peptide, and substance
P (Babiker et al., 2012) have shown that the diabetic
heart was resistant to a novel form of postconditoning
using pacing (10 cycles of 30 seconds left ventricular
pacing alternated with 30 seconds right atrial pacing)
compared with the nondiabetic heart.
Further studies have demonstrated that pharmaco-
logic postconditioning using a variety of agents can also
be affected by the presence of diabetes. Raphael et al.
(2010) found that hyperglycemia abrogated the cardio-
protection elicited by the inhaled anesthetic isoflurane,
administered at the onset of myocardial reperfusion,
using a rabbit in vivo model of acute ischemia/reperfusion
injury, a finding that was associated with impaired ac-
tivation of Akt-eNOS. Similarly, the infarct size–limiting
effect of the inhaled anesthetics desflurane (Tai et al.,
2012) and sevoflurane (Drenger et al., 2011), adminis-
tered at the onset of myocardial reperfusion to rats in
vivo, was abolished in the presence of diabetes. This was
associated with a failure of these anesthetic agents to
activate Akt, ERK1/2, GSK-3b (Tai et al., 2012), and
STAT3 (Drenger et al., 2011). An interesting study by
Potier et al. (2013) suggested that there may be dif-
ferential effects in the response to cardioprotection using
different bradykinin receptor agonists in the presence
of diabetes. It was shown that ischemic postcondition-
ing, the angiotensin-converting enzyme (ACE) inhibitor
ramiprilat or a bradykinin B2 receptor agonist, all reduced
infarct size and activated Akt, ERK1/2, and GSK-3b in
the nondiabetic heart but failed to do so in the diabetic
heart (Potier et al., 2013). In contrast, the diabetic heart,
but not the nondiabetic heart, was found to be amenable
to pharmacologic postconditioning using a bradykinin B1
receptor agonist (Potier et al., 2013).
A number of experimental studies have investigated
the cardioprotective effects of combining ischemic and
pharmacologic postconditioning in the diabetic heart.
Badalzadeh et al. (2012) demonstrated that the isolated
diabetic rat heart was resistant to cardioprotection by
either ischemic postconditioning or cyclosporine-A alone,
but with the combination of interventions, a significant
reduction in infarct size was observed. In contrast, Fan
et al. (2012) found that atorvastatin was able to post-
condition the diabetic heart, despite it being resistant to
ischemic postconditioning; when given in combination,
an additive cardioprotective effect was seen. These data
suggest that the diabetic heart may be amenable to
cardioprotection if the intensity of the postconditioning
stimulus is enhanced.
Attempts have been made to recapture the cardio-
protective effects of postconditioning by correcting the
hyperglycemic state. In this regard, although insulin
pretreatment failed to restore the sensitivity of the
diabetic heart to postconditioning (Drenger et al., 2011),
the transplantation of pancreatic islet tissue was able to
reverse the effect of diabetes on the myocardial response
to postconditioning (Przyklenk et al., 2011).
In contrast to the above findings, Lacerda et al.
(2012) found that despite the presence of diabetes, the
murine heart was equally sensitive to ischemic post-
conditioning (6  10-second cycles of coronary arterial
occlusion/reperfusion) as the nondiabetic heart. How-
ever, this discordant finding may in part be explained
by the fact that the streptozotocin-induced diabetes
was only initiated 5–10 days before MI. A recent study
by Oosterlinck et al. (2013), using a genetic murine
model of diabetes (ob/ob and DKO strains), demon-
strated that the cardioprotective effect of ischemic
postconditioning was attenuated, although this may in
part relate to the use of a nonstandard ischemic post-
conditioning protocol (3  10-second cycles of coronary
arterial occlusion/reperfusion).
Bouhidel et al. (2008) investigated the effect of obesity
alone on the efficacy of ischemic postconditioning. They
found that the leptin-deficient obese (ob/ob) mice were
resistant to cardioprotection by ischemic postcondition-
ing and that this was associated with an inability to
activate Akt, ERK1/2, p70S6 kinase, and AMPK. By
using a rat model of the metabolic syndrome, Wagner
et al. (2008) found that the Wistar-Ottawa-Karlsburg W
rats were resistant to the cardioprotection elicited by
ischemic postconditioning, and this was associated with
an inability to phosphorylate ERK1/2 and its down-
stream effector GSK-3b. Huhn et al. (2009b, 2010)
reported that the Zucker obese rat was resistant to
pharmacologic postconditioning using either sevoflurane
or cyclosporine-A. The finding that the presence of a
comorbidity could impact on the cardioprotective efficacy
of cyclosporine-A is somewhat surprising, because
its target, the MPTP, is believed to be downstream of
the signaling pathways affected by the comorbidity.
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However, one can speculate that the comorbidity may
interfere with cardioprotection by modulating mitochon-
drial function. An interesting study by Pons et al. (2013)
showed that regular treadmill exercise was able to
protect the heart in obese (ob/ob) mice through the
activation of prosurvival kinases (Akt, ERK1/2, GSK-3b,
p70S6 kinase, AMPK) and in the absence of any
improvement in metabolic profile. These findings sug-
gest that regular exercise may have beneficial effects on
the heart independently of any effect it may have on the
metabolic profile.
Despite the preclinical data demonstrating the
resistance of the diabetic heart to both ischemic and
pharmacologic postconditioning, there have been no
clinical trials investigating the effect of diabetes on the
cardioprotective efficacy of postconditioning. This is
despite a number of proof-of-concept clinical studies
comprising a significant proportion of diabetic pa-
tients, reporting beneficial effects of postconditioning
in STEMI and coronary artery bypass graft surgery
patients (see section III). Interestingly, Lemoine et al.
(2008, 2010, 2011) found that human atrial trabeculae
subjected to simulated acute ischemia/reperfusion
injury were equally sensitive to the cardioprotective
effects of pharmacologic postconditioning using des-
flurane, whether harvested from diabetic or nondiabetic
patients undergoing coronary artery bypass graft surgery.
4. Cardioprotection by Remote Ischemic Conditioning
in Diabetes. Despite the clinical potential of remote
ischemic conditioning, there is a paucity of animal data
investigating whether the diabetic heart is amenable
to this cardioprotective intervention. Investigating the
effect of diabetes in this setting can be quite challeng-
ing, given that the presence of diabetes may modulate
signaling at any one or more of the following stages of
the mechanistic pathway: the remote organ or tissue in
which the conditioning stimulus is applied, the neuro-
hormonal pathway that conveys the cardioprotective
stimulus to the heart, and finally, the activation of
intracellular prosurvival signaling pathways within
the heart (reviewed in Hausenloy and Yellon, 2008).
There has been only one experimental animal study
published specifically investigating the cardioprotec-
tive efficacy of remote ischemic preconditioning in the
presence of diabetes. Zhu et al. (2011b) found that the
diabetic rat heart in vivo was amenable to infarct size
reduction elicited by limb preconditioning (3  5-
minute cycles of hindlimb cuff inflation/deflation).
However, it is important to note that in this study
streptozotocin-induced diabetes was only initiated 1
week before MI. Whether remote ischemic precondi-
tioning would have been effective in a chronic diabetes
animal model remains to be determined.
Remote ischemic conditioning, using a cuff placed on
either the upper arm or leg to induce three or more cycles
of brief ischemia and reperfusion, has been reported to
have beneficial effects in a number of clinical settings
including STEMI patients treated by primary PCI,
coronary artery bypass graft patients, and patients
undergoing elective PCI (reviewed in Hausenloy and
Yellon, 2008; Candilio et al., 2011; Heusch, 2013).
Although many of these clinical studies included diabetic
patients they did not specifically address the question of
whether the diabetic heart was amenable to remote
ischemic conditioning.
Xu et al. (2014) found that a standard remote is-
chemic conditioning stimulus (3  5-minute upper arm
cuff inflations/deflation) did not reduce the magnitude
or incidence of periprocedural myocardial injury during
elective PCI in older patients (mean age 69 years) with
diabetes. However, it is difficult to distinguish the
effect of diabetes from that of age on the remote
ischemic preconditioning protocol. Furthermore, the
authors of this study did not demonstrate that their
remote ischemic preconditioning protocol was effective
in a younger nondiabetic population (Xu et al., 2014).
In an intriguing clinical study by Jensen et al. (2012) it
was reported that diabetic patients with a peripheral
neuropathy failed to produce a cardioprotective hu-
moral factor in response to a standard remote ischemic
preconditioning protocol (4  5-minute upper arm cuff
inflation/deflation) compared with nondiabetic and di-
abetic patients who did not have a peripheral neurop-
athy. This finding supports the notion that an intact
neural pathway from/to the remotely conditioned organ
or tissue is required to elicit the cardioprotective
humoral factor (Jensen et al., 2012). In this particular
study, the cardioprotective efficacy of the humoral
factor was tested in an isolated perfused rabbit heart
ischemia/reperfusion model, and therefore whether the
diabetic heart was amenable to remote ischemic
preconditioning cardioprotection was not actually in-
vestigated (Jensen et al., 2012). A later study by the
same research group investigated the impact of myo-
cardial O-linked b-N-acetylglucosamine (O-GlcNAc) in
remote ischemic preconditioning-induced protection
(Jensen et al., 2013). They found that plasma dialysate
harvested from either normal volunteers or diabetic
patients treated with a standard protocol of remote
ischemic preconditioning (3  5 cycles of upper am cuff
inflation/deflation) was able to protect naive human
right atrial trabeculae subjected to simulated ischemia/
reperfusion injury, findings which were associated with
increased levels of myocardial O-GlcNAc (Jensen et al.,
2013). These findings appear to suggest that increased
myocardial levels of O-GlcNAc may indicate a cardio-
protective phenotype.
In summary, the majority of both preclinical and
clinical data suggests that the diabetic heart is more
susceptible to ischemia/reperfusion injury and that the
cardioprotective effect of ischemic and pharmacologic
preconditioning and of postconditioning is impaired in
the presence of diabetes. This impairment appears to
be associated with deficient activation of prosurvival
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signaling pathways, such as Akt, ERK1/2, AMPK, and
STAT3. Due to the limited preclinical and clinical
studies available, whether the diabetic heart is
amenable to remote ischemic conditioning is currently
not known.
E. Kidney Failure and Uremia
Uremia, resulting from kidney failure, is a metabolic
disease associated with a high prevalence of ischemic
heart disease (Levey and Coresh, 2012). Therefore, one
may speculate that a uremic state may also lead to the
attenuation of endogenous cardioprotective mechanisms.
However, Byrne et al. (2012) reported that ischemic
preconditioning, remote conditioning, and postcondi-
tioning were still cardioprotective after 4 weeks of
subtotal nephrectomy or adenine-enriched diet–induced
acute uremia in rats. They also showed in this model
that the RISK and SAFE signaling pathways were
unaffected. However, experimental models of acute
uremia may not properly reflect the clinical situa-
tion, because uremia frequently remains unrecognized
until its late stages (Levey and Coresh, 2012). Kocsis
et al. (2012) studied if prolonged experimental uremia
of 30 weeks duration affects ischemic preconditioning.
They found that although prolonged experimental
uremia led to severe metabolic changes and mild
myocardial dysfunction, the cardioprotective effect of
ischemic preconditioning was still preserved 30 weeks
after partial nephrectomy in rat hearts. However, it
is not known if longer durations of uremia may in-
terfere with postconditioning or remote conditioning.
Human conditioning studies in uremia have not been
reported.
Taken together, the limited preclinical studies suggest
that despite the complex systemic metabolic changes in
uremia, cardioprotection by pre- and postconditioning is
preserved. Nevertheless, further preclinical studies in
long-term experimental uremia models, as well as
clinical studies, will be necessary to show if mechanical
or pharmacologic conditioning can still protect the heart
in uremic patients.
F. The Diseased Coronary Circulation
Experimental studies on myocardial ischemia/
reperfusion are usually performed in healthy young
animals; moreover, irrespective of age, these animals
have a virgin coronary circulation. In clinical reality,
atherosclerosis develops progressively over time. Plaque
fissure and rupture are then acutely superimposed on
the underlying atherosclerosis and further complicated
by intraluminal platelet aggregation and coagulation. In
contrast, experimental studies usually rely on abrupt
closure and reopening of the epicardial coronary artery
with external devices. Therefore, the status of both the
epicardial coronary arteries and the coronary microcir-
culation is vastly different between clinical reality and
most experimental models. We need to consider these
differences as confounders in translation of cardiopro-
tective strategies (Heusch et al., 2012a). In fact, in most
but not all of the more clinically relevant conditions,
a diseased coronary circulation tends to attenuate the
efficacy of cardioprotection.
1. Epicardial Coronary Arteries. Atherosclerotic plaque
rupture in an epicardial coronary artery with super-
imposed intraluminal thrombotic occlusion of the coro-
nary arterial lumen is the culprit event that causes
acute MI in the clinical setting. Primary PCI removes
the occlusive thrombus but—unless there is direct
stenting—leaves the underlying atherosclerotic vascular
lesion unaffected. Therefore, reperfusion does not occur
through a fully patent epicardial coronary artery but one
with a residual stenosis. As a consequence, there is not
abrupt, but attenuated, more gentle reperfusion. This
gentle reperfusion will be even more prominent when
thrombolysis is applied, giving slow thrombus dissolu-
tion. Gentle reperfusion per se attenuates reperfusion
injury and reduces infarct size (Heusch, 2004), as has
been demonstrated by gradual restoration of coronary
perfusion pressure in isolated rodent heart prepara-
tions (Nemlin et al., 2009) and slow restoration of
coronary blood flow in larger mammals in vivo (Musiolik
et al., 2010). Therefore, when comparing a group of
patients undergoing a conditioning intervention to a
purported control group, which inadvertently under-
goes gentle reperfusion through a residual stenosis
and thereby experiences some protection, the differ-
ence between the two groups that reflects the magnitude
of cardioprotection by the conditioning intervention
is diminished. Use of direct stenting removes any
residual stenosis and coronary microembolization
from the culprit lesion such that the consequences of
immediate full reperfusion in the control group are
compared with those of the postconditioning algo-
rithm in the intervention group (Loubeyre et al., 2002;
Heusch, 2012).
2. The Coronary Microcirculation. Plaque rupture is
not only the causal index event that leads to acute MI;
minor plaque fissure or rupture may also precede or
follow the index event, initiated either spontaneously
and/or after mechanical intervention. In the absence
of coronary occlusion, plaque fissure/rupture releases
particulate debris from the underlying atherosclerotic
lesion that is superimposed by intraluminal platelet
aggregates and coagulation material. These athero-
thrombotic particles are then washed into the coronary
microcirculation where they cause microembolization.
Coronary microembolization with inert particles in dogs
and pigs induces microinfarcts and an inflammatory
reaction (Heusch et al., 2009). However, in patients the
ruptured atherosclerotic plaque also releases soluble
vasoconstrictor, proinflammatory and prothrombotic
mediators that contribute to the impairment of coronary
microvascular perfusion (Kleinbongard et al., 2011).
Both the particulate debris and the soluble mediators
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not only impair coronary microvascular perfusion per se
but may also interfere with cardioprotective condition-
ing strategies.
As discussed previously (section III.A), preinfarction
angina is associated with cardioprotection and proba-
bly represents a clinical correlate of ischemic precon-
ditioning. In a pig model, coronary microembolization,
which may occur clinically during preinfarction angina,
induces microinfarcts that add to the aggregate infarct
size caused by the index MI. Coronary microemboliza-
tion with inert particles in pigs neither induces acute
ischemic preconditioning nor does it interfere with
acute ischemic preconditioning (Heusch et al., 2009).
However, on a somewhat more prolonged time frame,
coronary microembolization causes the upregulation of
TNFa over several hours, which then induces cardio-
protection (Skyschally et al., 2007); this form of
protection several hours after coronary microemboliza-
tion was termed a “third window of ischemic precondi-
tioning” (Heusch et al., 2007).
The no-reflow phenomenon is the most severe form of
coronary microvascular obstruction that occurs during
reperfusion after acute MI and is associated with
adverse prognosis. Embolization of atherothrombotic
debris, platelet and platelet/leukocyte aggregates, vaso-
constrictor substances, edema, and physical destruction
of the capillary bed all contribute to the no-reflow
phenomenon. Minor forms of microvascular obstruction
are frequently observed after elective and emergency
PCI (Heusch et al., 2013). Coronary microembolization
that occurs during early reperfusion may even be
initiated by interventional manipulation of the culprit
lesion, increasing infarct size. In a pig model of coronary
microembolization during early reperfusion, a redistri-
bution of embolizing particles into the infarct border
zone is causal for lateral extension of the infarct
(Skyschally et al., 2013). Many interventionalists
abstain from postconditioning maneuvers by further
manipulation of the culprit lesion after primarily
successful reperfusion for fear of causing coronary
microembolization and additional damage (Heusch,
2012). However, in pigs, ischemic postconditioning
is still effective in reducing infarct size even when
associated with coronary microembolization, albeit to
a lesser extent (Skyschally et al., 2013). Therefore, again
it appears wise to perform postconditioning after direct
stenting, which prevents coronary microembolization
from the culprit lesion (Loubeyre et al., 2002; Heusch,
2012).
Finally, we have to consider the impact of soluble
mediators released into the coronary circulation, which
not only contribute to microvascular obstruction per se
but may also induce cardioprotection. These include
notably TNFa (Skyschally et al., 2007; Kleinbongard
et al., 2010; Kleinbongard et al., 2011) and endothelin
(Kleinbongard et al., 2013a), but others might also be
implicated.
In summary, the coronary circulation is not only the
primary origin of myocardial infarction and reperfu-
sion, but also a major confounder of local cardiopro-
tective strategies, i.e., ischemic preconditioning and
postconditioning.
V. Effects of Concomitant Medications Used to
Treat Risk Factors and Comorbidities on
Cardioprotection: Hidden Cardiotoxicity?
Here we review recent data on the effect of the most
frequently encountered drug therapies for cardiovascu-
lar risk factors that may modify cardioprotective
mechanisms and thereby modify the efficacy of cardio-
protection (Table 3). Very little is known on the possible
unwanted effect of medications on the ischemic heart
and endogenous cardioprotection, which may result in
a latently developing cardiotoxicity (Golomb et al.,
2009), and which is now termed as “hidden cardiotox-
icity.” Hidden cardiotoxicty of a medication may not be
seen in the healthy heart but may manifest in only the
ischemic heart as an increased tissue injury due to an
increased sensitivity to an ischemic challenge or a de-
creased capability to adapt to an ischemic challenge.
A. Nitrates and Nitrate Tolerance
Organic nitrates have been used for more than 100
years to prevent and alleviate symptoms of angina
pectoris and to reduce blood pressure. However, the
main limitation of long-term prophylactic nitrate ther-
apy is the development of vascular nitrate tolerance,
which leads to the loss of clinical efficacy (see for review:
Csont and Ferdinandy, 2005; Csont, 2010). It has been
shown in preclinical studies that the presence of nitrate
tolerance aggravates ischemia/reperfusion injury and
leads to loss of the cardioprotective effect of precondi-
tioning (see for review Ferdinandy et al., 2007). Since
then, little progress has been made in this field.
Nevertheless, Fekete et al. (2013) recently showed that
the presence of nitrate tolerance inhibits the infarct size
limiting effect of postconditioning in rats. Moreover, in
a recent human study, Gori et al. (2010) reported that
the endothelial preconditioning effect of a single dose of
nitroglycerin is lost upon a prolonged exposure to
nitroglycerin. Nevertheless, the acute administration
of nitrates appears not to interfere with remote con-
ditioning in patients undergoing coronary artery bypass
graft surgery (Kleinbongard et al., 2013b).
B. Statins and Antihyperlipidemic Medication
A number of large clinical trials and meta-analyses
has shown that chronic administration of the most
frequently used antihyperlipidemic drugs, statins
(hydroxymethylglutarate CoA reductase inhibitors,
i.e., inhibitors of the mevalonate pathway), have potent
cholesterol-lowering effects and reduce cardiovascular
morbidity and mortality (Mills et al., 2011) even in
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low-risk patients (Mihaylova et al., 2012). However, it
seems that statin therapy is less effective in women
(Gutierrez et al., 2012). Because the anti-ischemic ef-
fect of rosuvastatin, as shown by improved flow-
mediated dilation after upper arm ischemia, may
disappear after chronic treatment in patients (Liuni
et al., 2012), acute statin loading therapy has been
recommended for PCI recently (Benjo et al., 2014).
However, acute statin therapy was found ineffective in
a recent clinical trial in low-risk PCI patients (Ludman
et al., 2011). The possible mechanisms of the statin-
induced cardioprotective effect are reviewed elsewhere
(Ludman et al., 2009; Mahalwar and Khanna, 2013).
We previously reviewed that statins protect the
heart against ischemia/reperfusion injury in preclinical
studies but may interfere with the infarct size-limiting
effect of preconditioning (see Ferdinandy et al., 2007).
However, very little is known on the possible inter-
actions of statins with cardioprotection by conditioning
strategies. Kocsis et al. (2008) showed that precondi-
tioning failed to decrease infarct size in rat hearts
treated acutely with lovastatin and that postcondition-
ing failed to decrease infarct size after chronic
lovastatin treatment. In this study, myocardial levels
of coenzyme Q9 and phosphorylation of Akt were
decreased due to lovastatin treatment. Moreover,
acute, but not chronic lovastatin treatment increased
the phosphorylation of p42 ERK. Szucs et al. (2013)
recently showed that activation of the mevalonate
pathway with farnesol is cardioprotective; thus, one
may speculate that inhibition of this pathway by
statins may interfere with cardioprotective mecha-
nisms. Accordingly, chronic atorvastatin treatment in
diabetic rats with postconditioning failed to show any
cardioprotection (Fan et al., 2012). Upregulation by
statins of PTEN, which then dephosphorylates PI3K,
might contribute to the lack of endogenous cardiopro-
tection after long-term statin treatment (Schulz, 2005).
In rabbits, short-term simvastatin treatment and
postconditioning were unable to reduce infarct size,
but pravastatin decreased infarct size, possibly via
eNOS activation (Andreadou et al., 2012). Chronic
simvastatin treatment, in contrast to postconditioning, was
able to reduce infarct size in both normocholesterolemic
and hypercholesterolemic rabbits (Iliodromitis et al.,
2010). The effect of statins on remote conditioning has
not yet been reported.
In summary, although statins show a potential
cardioprotective effect, some statins, depending on the
duration of treatment, may interfere with the mecha-
nisms of cardiac adaptation to ischemia/reperfusion
stress. This may represent an uncharacterized delete-
rious effect of statins. Further preclinical and clinical
studies are needed to explore the effect of statins on
cardioprotection by conditioning strategies. Neverthe-
less, the development of novel lipid-lowering agents that
do not interfere with innate mechanisms of cardiac
stress adaptation may further improve the efficacy of
lipid-lowering therapy in the prevention of cardiovascu-
lar events in hypercholesterolemic patients.
C. Antidiabetic Therapy
The treatments used to lower blood glucose levels in
diabetic patients may impact on the cardioprotective
efficacy of "conditioning" strategies by modulating the
underlying intracellular signaling pathways within
the heart in two major ways. The antidiabetic therapy
may either interfere with the cardioprotective signal-
ing pathway, thereby blocking the "conditioning"
strategy, or it may mimic the "conditioning" strategy,
thereby inducing cardioprotection (reviewed in Ferdinandy
et al., 2007; Ye et al., 2011). Through these effects,
there is the potential for antidiabetic therapies to
impact on long-term cardiac outcomes in diabetic
patients.
In 2008, the US Food and Drug Administration
issued requirements that novel antidiabetic drugs
must be shown not to increase the risk of cardiovas-
cular events. It is well established that antidiabetic
therapy can prevent microvascular complications of
diabetes, but whether it can also reduce macrovascular
complications and improve major cardiovascular out-
comes, such as myocardial infarction, stroke, heart
failure, and fatal arrhythmias, is unresolved.
TABLE 3
Effect of most common medications of cardiovascular risk factors on ischemia/reperfusion (I/R) injury as
well as pre-, post-, and remote conditioning in the majority of the studies
It should be noted that very few data are available so far on the effect of medications on conditioning strategies.
Medication I/R Injury Preconditioning Postconditioning Remote Conditioning
Nitrate tolerance ↑ ↓ ↓ N.D.
Statins ↓ ↓ ↓ N.D.
Antidiabetics
KATP inhibitors ↑ ↓ ↓ ↓
Others ↓ — — N.D.
b-Blockers ↓ ↓— — N.D.
ACE inhibitors ↓ ↑ N.D. N.D.
AT1 antagonists ↓ ↑ N.D. N.D.
Calcium channel blockers ↓— — N.D. N.D.
COX inhibitors ↑ N.D. N.D. N.D.
N.D., no data available; ↑, enhance, ↓, attenuate, —, no effect.
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1. Antidiabetic Therapy and ATP-Sensitive Potas-
sium Channels. The activation of either the sarcolemmal
or mitochondrial KATP channel within the cardiomyocyte
is a critical step in the signaling pathway underlying
both preconditioning and postconditioning (Ferdinandy
et al., 2007; Hausenloy, 2013). It is well established
in the preclinical literature that some long-acting
antidiabetic sulfonylureas (such as tolbutamide and
glibenclamide), which act by blocking KATP channel
activity in the pancreas to promote insulin release,
also interfere with the signaling pathway underlying
preconditioning and postconditioning by antagonizing
KATP channel activity within the cardiomyocyte (re-
viewed in Ye et al., 2011). However, some of the newer
shorter-acting antidiabetic sulfonylureas, such as
gliclazide and glimepiride, do not appear to interfere
with cardioprotection (Wu et al., 2007). A recent meta-
analysis has confirmed that sulphonylurea use may
elevate the risk of cardiovascular disease among pa-
tients with diabetes (Phung et al., 2013), although one
long-term clinical outcome study failed to report any
increase in cardiovascular events in diabetic patients
treated with glibenclamide compared with gliclazide
(Juurlink et al., 2012).
2. Antidiabetic Therapy with Mixed Actions on
Cardioprotection. A number of antidiabetic agents which
are used to treat hyperglycemia in diabetic patients are
known to confer cardioprotection; many of these appear to
act through the activation of the signaling pathways
underlying "conditioning" interventions.
Experimental studies have previously established
that the antidiabetic agents insulin and metformin can
confer cardioprotection in animal MI models (Bhamra
et al., 2008; Whittington et al., 2013a). Some of the
newer antidiabetic agents have also been reported to
limit infarct size in the diabetic and nondiabetic heart,
including 1) thiazolidinediones, such as rosiglitazone
(Morrison et al., 2011; Palee et al., 2013) and pioglitazone
(Ye et al., 2008; 2010a); 2) GLP-1 analogs, such as
liraglutide (Noyan-Ashraf et al., 2009) and exenatide
(Timmers et al., 2009); and 3) dipeptidyl peptidase-4
inhibitors, such as sitagliptin (Sauve et al., 2010; Ye
et al., 2010a; Hausenloy et al., 2013b) and vildagliptin
(Hausenloy et al., 2013b). The novel antidiabetic
agent mitiglinide (Ogawa et al., 2007) has been found
to affect the efficacy of preconditioning or postcondi-
tioning in the diabetic heart. However, not all studies
have reported cardioprotective effects with these
antidiabetic agents (Kristensen et al., 2009; Yin et al.,
2011).
A number of clinical studies have either investigated
whether antidiabetic agents abolish cardioprotection
or have investigated the antidiabetic agent as a ther-
apeutic intervention for limiting MI size. Large long-
term clinical outcome studies have examined the effect
of the antidiabetic therapy on major cardiovascular
events. Hueb et al. (2007) demonstrated in diabetic
patients that treatment with repaglinide (a KATP
channel antagonist) blocked the ischemic precondition-
ing effect against exercise-induced myocardial ische-
mia. Using a similar clinical model, Rahmi et al. (2013)
confirmed the negative effect of repaglinide on pre-
conditioning but also found that vildagliptin did not
block preconditioning’s protection. The protection by
remote ischemic preconditioning is abrogated in di-
abetic CABG patients when treated with sulphonylureas
(Kottenberg et al., 2014b).
Administration of the GLP-1 analog exenatide at the
time of myocardial reperfusion has been reported to
reduce infarct size in STEMI patients treated by
primary PCI in two proof-of-concept clinical studies
(Lonborg et al., 2012; Woo et al., 2013). The recent
IMMEDIATE trial suggests that the beneficial effect of
glucose-insulin-potassium therapy in STEMI patients
may indeed be operative if administered in the
ambulance en route to the primary PCI center while
ischemia is ongoing (Selker et al., 2012).
A number of large multicenter long-term clinical
outcome studies have reported mixed results in terms
of their impact on major ischemia-related cardiovascu-
lar outcomes with either better [metformin (Roussel
et al., 2010)], worse [rosiglitazone (Nissen and Wolski,
2007)], or no effect [alogliptin (White et al., 2013) and
saxagliptin (Scirica et al., 2013)].
In summary, it is important to appreciate that many
antidiabetic therapies can either interfere with or
mimic the cardioprotective intervention under investi-
gation. It is important to take this into account when
designing clinical studies of cardioprotection in di-
abetic patients.
D. b-Adrenoceptor Antagonists
The effect of ischemic preconditioning was abolished in
isolated rat hearts after long-term oral treatment with
propranolol or nipradilol (Suematsu et al., 2004). In
contrast, landilol treatment during ischemic precondi-
tioning in isolated rat hearts (Yu et al., 2010) or
intravenous atenolol or esmolol, given before ischemia
or at reperfusion, did not interfere with protection
afforded by ischemic preconditioning in rabbit hearts in
vivo (Iliodromitis et al., 2004). However, esmolol abol-
ished the infarct size reduction achieved by flurane-
induced anesthetic preconditioning (Lange et al., 2006).
In isolated rat cardiomyocytes, hypoxia or anesthesia-
induced 24-hour delayed preconditioning was abolished
by metoprolol (Goetzenich et al., 2011). Similarly,
anesthesia-induced postconditioning was mediated in
part by b-adrenergic signaling as infarct size reduction
was again blocked by esmolol (Lange et al., 2009).
Although b-blockers might thus interfere with the
protection afforded by preconditioning and postcondition-
ing in healthy hearts in vivo, carvedilol restored the
protection by ischemic preconditioning (Watanabe et al.,
2006) or postconditioning (Oikawa et al., 2008) that was
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otherwise lost in hearts with a chronic coronary artery
stenosis.
Most recently, a meta-analysis of 15 trials with a total
of 1155 patients confirmed that remote ischemic
preconditioning significantly reduced postoperative bio-
markers of myocardial injury, and this effect was most
significant in valve surgery and to a lesser extent in
coronary artery bypass graft surgery. One major source
of heterogeneity in the protective effect was the use of
b-blockers, suggesting that these drugs might attenuate
the cardioprotective effect of remote ischemic precondi-
tioning in patients (Zhou et al., 2013).
Currently, there is no clear answer yet as to whether
b-blockers impact on endogenous cardioprotective sig-
naling. However, the data provided so far highlight the
need for further studies and more detailed analyses,
given the widespread use of b-blocker therapy.
E. Angiotensin-Converting Enzyme Inhibitors/
Angiotensin II Receptor Type 1 Receptor Antagonists
ACE inhibitors and angiotensin II receptor type 1
(AT1) receptor antagonists when administered before
ischemia and/or reperfusion reduce irreversible myo-
cardial injury (Jalowy et al., 1998; Jancso et al., 2004;
Messadi et al., 2010). However, the beneficial effects of
ACE inhibitors and/or AT1 receptor antagonists be-
come attenuated when cyclooxygenase-2 (COX-2) in-
hibitors are simultaneously applied (Jalowy et al.,
1998). Both ACE inhibitors and AT1 receptor antago-
nists lower the threshold to achieve endogenous car-
dioprotection, especially in hearts with comorbidities
(Jaberansari et al., 2001; Ebrahim et al., 2007; Penna
et al., 2010).
F. Calcium Channel Blockers
L-type calcium channel blockers (CCBs) are widely
used as antianginal and antihypertensive drugs. Ex-
perimentally, they reduce infarct size in almost all animal
models of MI, with no apparent chemical class differ-
ences between different CCBs (i.e. 1,4-dihydropyridines,
verapamil, or diltiazem). However, protection is con-
sistently higher when treatment is started before or
during early ischemia, with little benefit seen when
the agents are given at reperfusion (Kleinbongard
et al., 2012). Contrary to the promising experimental
data, clinical trials in acute MI have been disappoint-
ing (Opie et al., 2000), probably because the agents
need to be given before the onset of ischemia or during
the early ischemic phase. Although studies on post- or
remote conditioning and CCBs are lacking, a single
study in pigs demonstrated no interference of CCBs with
cardioprotection by ischemic preconditioning (Wallbridge
et al., 1996).
G. Cyclooxygenase Inhibitors
COX-2 is involved in the protective signaling of
preconditioning and postconditioning (Alcindor et al.
2004; Sato et al., 2007; Penna et al., 2008; Tosaka et al.,
2011). Blockade of COX-2 can abolish the cardioprotec-
tive phenomena, most importantly delayed or second
window preconditioning (Przyklenk and Heusch, 2003;
Huhn et al., 2009a; Guo et al., 2012). High-dose aspirin,
which blocks both COX-1 and COX-2, interferes with
endogenous cardioprotection (Ye et al., 2010b). Never-
theless, many patients with an acute MI receive
high-dose aspirin (.300 mg) orally or intravenously.
Whether patient outcome would be improved with lower
doses of aspirin remains to be elucidated, although
recently COX-2 inhibition was found to increase mor-
tality in patients post-MI (Olsen et al., 2012). Again,
whether such increase in mortality relates to the at-
tenuation of endogenous cardioprotective phenomena
or is a consequence of reduced endothelial prostacyclin
production on susceptibility to thrombosis remains
unanswered.
VI. Conclusions and Future Perspectives
The discovery of the remarkable cardioprotective
effect of innate adaptive responses elicited by different
conditioning strategies has fuelled intensive research
in the last three decades to find key cellular mecha-
nisms and drug targets for pharmacologic cardiopro-
tection as well as clinically applicable protocols for
mechanical cardioprotection. Given the global scale of
ischemic heart disease, surprisingly little effort has
been made to uncover the cellular mechanisms by
which major cardiovascular risk factors (see section IV)
and their medications (see section V) may interfere
with cardioprotective mechanisms.
Most of the clinical trials with potential cardiopro-
tective drugs have been unsuccessful so far. One of the
reasons might be that target validation and preclinical
efficacy and safety studies have been performed in juvenile,
healthy animals subjected to ischemia/reperfusion in-
jury. Here we have indicated data suggesting that
validation of drug targets in comorbid animal models
would be essential for successful clinical translation (see
section IV.C.2). Furthermore, we have highlighted that
routine medications for cardiovascular and other dis-
eases may exert undesirable effects on the ischemic heart
and cardioprotective signaling mechanisms, thereby
possessing an as yet largely unexplored “hidden cardio-
toxicity” (see section V).
Proof-of-principle studies using mechanical condition-
ing strategies in patients undergoing elective, emergency,
or surgical coronary revascularization have success-
fully translated cardioprotection from animal experi-
ments to human studies, although there are several
negative studies (see section III). The reasons for the
negative studies can be attributed to the presence of
risk factors, comorbidities, and their medications in
different patient cohorts. So far, such clinical studies
have been completed in small cohorts of selected
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patients under tightly controlled conditions, usually
with surrogate rather than clinical outcome endpoints.
However, ongoing clinical outcome studies (e.g. CIRCUS,
ERICCA, RIPHeart) will further determine whether
ischemic conditioning can improve clinical outcomes in
different patient cohorts.
The body of evidence we have reviewed here under-
scores the critical importance of preclinical models and
study designs that address cardioprotection specifically
in relation to complicating disease states and risk fac-
tors. This more sophisticated approach is now an ur-
gent necessity in experimental cardioprotection research
to maximize the likelihood of identifying translatable
effective approaches to therapeutic protection of the aged
or diseased ischemic heart.
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